CA2088490A1 - 3-substituted piperidine derivatives - Google Patents
3-substituted piperidine derivativesInfo
- Publication number
- CA2088490A1 CA2088490A1 CA002088490A CA2088490A CA2088490A1 CA 2088490 A1 CA2088490 A1 CA 2088490A1 CA 002088490 A CA002088490 A CA 002088490A CA 2088490 A CA2088490 A CA 2088490A CA 2088490 A1 CA2088490 A1 CA 2088490A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pentylpiperidine
- phenyl
- compounds
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 3-substituted piperidine Chemical class 0.000 title description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 145
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 18
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000001301 oxygen Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000005864 Sulphur Substances 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 6
- 125000003118 aryl group Chemical group 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 6
- MJYFVDNMTKLGTH-UHFFFAOYSA-N 4-bromo-6-(3,4-dichlorophenyl)sulfanyl-1-[[4-(dimethylcarbamoyl)phenyl]methyl]indole-2-carboxylic acid Chemical compound BrC1=C2C=C(N(C2=CC(=C1)SC1=CC(=C(C=C1)Cl)Cl)CC1=CC=C(C=C1)C(N(C)C)=O)C(=O)O MJYFVDNMTKLGTH-UHFFFAOYSA-N 0.000 claims abstract 6
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 238000009825 accumulation Methods 0.000 claims description 4
- 210000004958 brain cell Anatomy 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 150000001340 alkali metals Chemical group 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 239000012038 nucleophile Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- LELNJGJCQOJQBJ-UHFFFAOYSA-N 1-pentyl-3-[(2-phenylphenoxy)methyl]piperidine Chemical compound C1N(CCCCC)CCCC1COC1=CC=CC=C1C1=CC=CC=C1 LELNJGJCQOJQBJ-UHFFFAOYSA-N 0.000 claims 1
- WWFYUVKNMOFGSR-UHFFFAOYSA-N 1-pentyl-3-[(3-phenylphenoxy)methyl]piperidine Chemical compound C1N(CCCCC)CCCC1COC1=CC=CC(C=2C=CC=CC=2)=C1 WWFYUVKNMOFGSR-UHFFFAOYSA-N 0.000 claims 1
- PUZHRYBYNXAUEU-UHFFFAOYSA-N 1-pentyl-3-[(4-phenylmethoxyphenoxy)methyl]piperidine Chemical compound C1N(CCCCC)CCCC1COC(C=C1)=CC=C1OCC1=CC=CC=C1 PUZHRYBYNXAUEU-UHFFFAOYSA-N 0.000 claims 1
- CJPWBGLSTYJLCW-UHFFFAOYSA-N 1-pentyl-3-[(4-phenylphenoxy)methyl]piperidine Chemical compound C1N(CCCCC)CCCC1COC1=CC=C(C=2C=CC=CC=2)C=C1 CJPWBGLSTYJLCW-UHFFFAOYSA-N 0.000 claims 1
- YITSLQRXVSYBCB-UHFFFAOYSA-N 1-pentyl-3-[(4-propan-2-ylphenoxy)methyl]piperidine Chemical compound C1N(CCCCC)CCCC1COC1=CC=C(C(C)C)C=C1 YITSLQRXVSYBCB-UHFFFAOYSA-N 0.000 claims 1
- LJGCRYAMJZEMHR-UHFFFAOYSA-N 1-pentyl-3-[[3-(trifluoromethyl)phenoxy]methyl]piperidine Chemical compound C1N(CCCCC)CCCC1COC1=CC=CC(C(F)(F)F)=C1 LJGCRYAMJZEMHR-UHFFFAOYSA-N 0.000 claims 1
- IPXAFMGFFGVCIN-UHFFFAOYSA-N 3,4-dichloro-n-[(1-pentylpiperidin-3-yl)methyl]aniline Chemical compound C1N(CCCCC)CCCC1CNC1=CC=C(Cl)C(Cl)=C1 IPXAFMGFFGVCIN-UHFFFAOYSA-N 0.000 claims 1
- WDOHUEFGFMHWDK-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-1-pentylpiperidine Chemical compound C1N(CCCCC)CCCC1COC1=CC=C(OCO2)C2=C1 WDOHUEFGFMHWDK-UHFFFAOYSA-N 0.000 claims 1
- USDSIEIKHQQHER-UHFFFAOYSA-N 3-[(2-benzylphenoxy)methyl]-1-pentylpiperidine Chemical compound C1N(CCCCC)CCCC1COC1=CC=CC=C1CC1=CC=CC=C1 USDSIEIKHQQHER-UHFFFAOYSA-N 0.000 claims 1
- LNDNXWAZAZTURI-UHFFFAOYSA-N 3-[(3,4-dichlorophenoxy)methyl]-1-(3-phenylprop-2-enyl)piperidine Chemical compound C1=C(Cl)C(Cl)=CC=C1OCC1CN(CC=CC=2C=CC=CC=2)CCC1 LNDNXWAZAZTURI-UHFFFAOYSA-N 0.000 claims 1
- QNGGMIAQIBEWLH-UHFFFAOYSA-N 3-[(4-benzylphenoxy)methyl]-1-pentylpiperidine Chemical compound C1N(CCCCC)CCCC1COC(C=C1)=CC=C1CC1=CC=CC=C1 QNGGMIAQIBEWLH-UHFFFAOYSA-N 0.000 claims 1
- ZBFJCZSXXOVMTG-UHFFFAOYSA-N 3-[(4-fluorophenoxy)methyl]-1-pentylpiperidine Chemical compound C1N(CCCCC)CCCC1COC1=CC=C(F)C=C1 ZBFJCZSXXOVMTG-UHFFFAOYSA-N 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 98
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 97
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 55
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 229940093499 ethyl acetate Drugs 0.000 description 32
- 235000019439 ethyl acetate Nutrition 0.000 description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
- 239000007787 solid Substances 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 23
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 23
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 22
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 22
- 239000002904 solvent Substances 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- LCDAPADGOWKBDM-UHFFFAOYSA-N (1-pentylpiperidin-3-yl)methanol Chemical compound CCCCCN1CCCC(CO)C1 LCDAPADGOWKBDM-UHFFFAOYSA-N 0.000 description 15
- 235000006408 oxalic acid Nutrition 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 229960004132 diethyl ether Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WDNBURPWRNALGP-UHFFFAOYSA-N 3,4-Dichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1 WDNBURPWRNALGP-UHFFFAOYSA-N 0.000 description 3
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- VLJSLTNSFSOYQR-UHFFFAOYSA-N 3-propan-2-ylphenol Chemical compound CC(C)C1=CC=CC(O)=C1 VLJSLTNSFSOYQR-UHFFFAOYSA-N 0.000 description 2
- YQUQWHNMBPIWGK-UHFFFAOYSA-N 4-isopropylphenol Chemical compound CC(C)C1=CC=C(O)C=C1 YQUQWHNMBPIWGK-UHFFFAOYSA-N 0.000 description 2
- 206010065040 AIDS dementia complex Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- IOOAFNHLWLQSMN-UHFFFAOYSA-N [1-(3-phenylprop-2-enyl)piperidin-3-yl]methanol Chemical compound C1C(CO)CCCN1CC=CC1=CC=CC=C1 IOOAFNHLWLQSMN-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 2
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical compound C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000002800 charge carrier Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- WLCAJVVSNAVBSM-UHFFFAOYSA-N oxalic acid;piperidine Chemical compound C1CCNCC1.OC(=O)C(O)=O WLCAJVVSNAVBSM-UHFFFAOYSA-N 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- VICBRGXAKKXPHC-UHFFFAOYSA-N (1-pentylpiperidin-3-yl)methyl methanesulfonate;hydrochloride Chemical compound Cl.CCCCCN1CCCC(COS(C)(=O)=O)C1 VICBRGXAKKXPHC-UHFFFAOYSA-N 0.000 description 1
- IXHNFOOSLAWRBQ-UHFFFAOYSA-N (3,4-dichlorophenyl)methanamine Chemical group NCC1=CC=C(Cl)C(Cl)=C1 IXHNFOOSLAWRBQ-UHFFFAOYSA-N 0.000 description 1
- YKYOIMJLSMZUBA-VAWYXSNFSA-N (e)-n-(2-methylpropyl)undec-2-en-8,10-diynamide Chemical compound CC(C)CNC(=O)\C=C\CCCCC#CC#C YKYOIMJLSMZUBA-VAWYXSNFSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- IZXWCDITFDNEBY-UHFFFAOYSA-N 1-(chloromethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCl)C=C1 IZXWCDITFDNEBY-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QMKAORSYTLYVMI-UHFFFAOYSA-N 1-pentyl-3-[(4-phenylmethoxyphenoxy)methyl]piperidine;hydrochloride Chemical compound Cl.C1N(CCCCC)CCCC1COC(C=C1)=CC=C1OCC1=CC=CC=C1 QMKAORSYTLYVMI-UHFFFAOYSA-N 0.000 description 1
- GCKVWISZYQQXTN-UHFFFAOYSA-N 1-pentyl-3-[(4-propan-2-ylphenoxy)methyl]piperidine;hydrochloride Chemical compound Cl.C1N(CCCCC)CCCC1COC1=CC=C(C(C)C)C=C1 GCKVWISZYQQXTN-UHFFFAOYSA-N 0.000 description 1
- UPMNYSLERSERFU-UHFFFAOYSA-N 2,4,6-tritert-butyl-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=C(C(C)(C)C)C=C(C(C)(C)C)C=C1C(C)(C)C UPMNYSLERSERFU-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- CDMGNVWZXRKJNS-UHFFFAOYSA-N 2-benzylphenol Chemical compound OC1=CC=CC=C1CC1=CC=CC=C1 CDMGNVWZXRKJNS-UHFFFAOYSA-N 0.000 description 1
- IPWLTZJKZZCPPQ-UHFFFAOYSA-N 2-ethyl-n-[(4-fluorophenyl)methyl]-4-piperidin-1-ylbutan-1-amine Chemical compound C=1C=C(F)C=CC=1CNCC(CC)CCN1CCCCC1 IPWLTZJKZZCPPQ-UHFFFAOYSA-N 0.000 description 1
- 229940061334 2-phenylphenol Drugs 0.000 description 1
- TYHXYRALWDJPOM-UHFFFAOYSA-N 3,4-dichloro-n-[(1-pentylpiperidin-3-yl)methyl]aniline;dihydrochloride Chemical compound Cl.Cl.C1N(CCCCC)CCCC1CNC1=CC=C(Cl)C(Cl)=C1 TYHXYRALWDJPOM-UHFFFAOYSA-N 0.000 description 1
- SDYWXFYBZPNOFX-UHFFFAOYSA-N 3,4-dichloroaniline Chemical group NC1=CC=C(Cl)C(Cl)=C1 SDYWXFYBZPNOFX-UHFFFAOYSA-N 0.000 description 1
- QYMDFARODZMOIR-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-1-pentylpiperidine;hydrochloride Chemical compound Cl.C1N(CCCCC)CCCC1COC1=CC=C(OCO2)C2=C1 QYMDFARODZMOIR-UHFFFAOYSA-N 0.000 description 1
- GJPHOUTZYPLZJW-UHFFFAOYSA-N 3-(1-pentylpiperidin-3-yl)propan-1-ol Chemical compound CCCCCN1CCCC(CCCO)C1 GJPHOUTZYPLZJW-UHFFFAOYSA-N 0.000 description 1
- WOHSAKWWCKGRAT-UHFFFAOYSA-M 3-(1-pentylpyridin-1-ium-3-yl)propan-1-ol;bromide Chemical compound [Br-].CCCCC[N+]1=CC=CC(CCCO)=C1 WOHSAKWWCKGRAT-UHFFFAOYSA-M 0.000 description 1
- UGEJOEBBMPOJMT-UHFFFAOYSA-N 3-(trifluoromethyl)phenol Chemical compound OC1=CC=CC(C(F)(F)F)=C1 UGEJOEBBMPOJMT-UHFFFAOYSA-N 0.000 description 1
- UDWLEOUINOCAJB-UHFFFAOYSA-N 3-[(2-benzylphenoxy)methyl]-1-pentylpiperidine;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(CCCCC)CCCC1COC1=CC=CC=C1CC1=CC=CC=C1 UDWLEOUINOCAJB-UHFFFAOYSA-N 0.000 description 1
- FBESMXHISZHMKP-UHFFFAOYSA-N 3-[(4-benzylphenoxy)methyl]-1-pentylpiperidine;hydrochloride Chemical compound Cl.C1N(CCCCC)CCCC1COC(C=C1)=CC=C1CC1=CC=CC=C1 FBESMXHISZHMKP-UHFFFAOYSA-N 0.000 description 1
- BUOCKSLFZZVZQB-UHFFFAOYSA-N 3-[(4-fluorophenoxy)methyl]-1-pentylpiperidine;oxalic acid Chemical compound OC(=O)C(O)=O.C1N(CCCCC)CCCC1COC1=CC=C(F)C=C1 BUOCKSLFZZVZQB-UHFFFAOYSA-N 0.000 description 1
- UJZQWZJWUWQCSO-UHFFFAOYSA-N 3-[(4-tert-butylphenoxy)methyl]-1-pentylpiperidine Chemical compound C1N(CCCCC)CCCC1COC1=CC=C(C(C)(C)C)C=C1 UJZQWZJWUWQCSO-UHFFFAOYSA-N 0.000 description 1
- RUROFEVDCUGKHD-UHFFFAOYSA-N 3-bromoprop-1-enylbenzene Chemical compound BrCC=CC1=CC=CC=C1 RUROFEVDCUGKHD-UHFFFAOYSA-N 0.000 description 1
- ZUGAIMFLQLPTKB-UHFFFAOYSA-N 3-pyridin-3-ylpropan-1-ol Chemical compound OCCCC1=CC=CN=C1 ZUGAIMFLQLPTKB-UHFFFAOYSA-N 0.000 description 1
- CYEKUDPFXBLGHH-UHFFFAOYSA-N 3-tert-Butylphenol Chemical compound CC(C)(C)C1=CC=CC(O)=C1 CYEKUDPFXBLGHH-UHFFFAOYSA-N 0.000 description 1
- HJSPWKGEPDZNLK-UHFFFAOYSA-N 4-benzylphenol Chemical compound C1=CC(O)=CC=C1CC1=CC=CC=C1 HJSPWKGEPDZNLK-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical group NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- QHPQWRBYOIRBIT-UHFFFAOYSA-N 4-tert-butylphenol Chemical compound CC(C)(C)C1=CC=C(O)C=C1 QHPQWRBYOIRBIT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000917105 Forda Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DDSZWBCJXDRQDU-UHFFFAOYSA-N [N].C1CCNCC1 Chemical group [N].C1CCNCC1 DDSZWBCJXDRQDU-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- XDFCIPNJCBUZJN-UHFFFAOYSA-N barium(2+) Chemical compound [Ba+2] XDFCIPNJCBUZJN-UHFFFAOYSA-N 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- UBXYXCRCOKCZIT-UHFFFAOYSA-N biphenyl-3-ol Chemical compound OC1=CC=CC(C=2C=CC=CC=2)=C1 UBXYXCRCOKCZIT-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000668 effect on calcium Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- YXOFBNFJWYFWQQ-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-1-(1-pentylpiperidin-3-yl)methanamine Chemical compound C1N(CCCCC)CCCC1CNCC1=CC=C(Cl)C(Cl)=C1 YXOFBNFJWYFWQQ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- AMYXARSJJARGKJ-UHFFFAOYSA-N oxalic acid;1-pentyl-3-[(2-phenylphenoxy)methyl]piperidine Chemical compound OC(=O)C(O)=O.C1N(CCCCC)CCCC1COC1=CC=CC=C1C1=CC=CC=C1 AMYXARSJJARGKJ-UHFFFAOYSA-N 0.000 description 1
- CXCDAANFFZJSFB-UHFFFAOYSA-N oxalic acid;1-pentyl-3-[(3-phenylphenoxy)methyl]piperidine Chemical compound OC(=O)C(O)=O.C1N(CCCCC)CCCC1COC1=CC=CC(C=2C=CC=CC=2)=C1 CXCDAANFFZJSFB-UHFFFAOYSA-N 0.000 description 1
- CYDGRZVWEAXTAG-UHFFFAOYSA-N oxalic acid;1-pentyl-3-[(4-phenylphenoxy)methyl]piperidine Chemical compound OC(=O)C(O)=O.C1N(CCCCC)CCCC1COC1=CC=C(C=2C=CC=CC=2)C=C1 CYDGRZVWEAXTAG-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910003445 palladium oxide Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- VUNPWIPIOOMCPT-UHFFFAOYSA-N piperidin-3-ylmethanol Chemical compound OCC1CCCNC1 VUNPWIPIOOMCPT-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical group OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compounds of structure (I) in which R is C1-8alkyl(phenyl)p, C2-8alkenyl(phenyl)p, C2-8alkynyl(phenyl)p, C3-8cycloalkyl or C1-8alkylC3-8cycloalkyl; p is 0 to 2; n is 0 to 6; A is a bond, oxygen, sulphur or NR1; R1 is hydrogen, C1-8alkyl or phenylC1-4alkyl; m is 0 to 3; and Ar is aryl or heteroaryl, each of which may be optionally substituted, and salts thereof;
processes for preparing compounds (I), pharmaceutical compositions containing them and their use in medicine, in particular as calcium blocking agents.
processes for preparing compounds (I), pharmaceutical compositions containing them and their use in medicine, in particular as calcium blocking agents.
Description
W O 92/02501 ~ ~ 3 3 ~ ~ o P(~r/GB91/01339 The present invention relates to 3-substituted piperidine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
The present invention therefore provides, in a first aspect, compounds of structure (I):
(CH2)nA~CH2)mAr ~ J (I) N
R
in which R is Cl_8alkyl(phenyl)p, C2_8alkenyl(phenyl)p, C2_8alkynyl~phenyl)p, C3_8cycloalkyl or cl-8alkylc3-8cycloalkyl;
p is 0 to 2;
n is 0 to 6;
A is a bond, oxygen, sulphur or NRl;
Rl is hydrogen, Cl_8alkyl or phenylCl_4alkyl;
m is 0 to 3; and Ar is aryl or heteroaryl, each of which may be optionally substituted, and salts thereof.
The present invention therefore provides, in a first aspect, compounds of structure (I):
(CH2)nA~CH2)mAr ~ J (I) N
R
in which R is Cl_8alkyl(phenyl)p, C2_8alkenyl(phenyl)p, C2_8alkynyl~phenyl)p, C3_8cycloalkyl or cl-8alkylc3-8cycloalkyl;
p is 0 to 2;
n is 0 to 6;
A is a bond, oxygen, sulphur or NRl;
Rl is hydrogen, Cl_8alkyl or phenylCl_4alkyl;
m is 0 to 3; and Ar is aryl or heteroaryl, each of which may be optionally substituted, and salts thereof.
2 ~ 9 0 - 2 -Suitably, R is Cl_8alkyl(phenyl)p, C2_8alkenyl-(phenyl)p, C2_8alkynyl(phenyl)p, C3_8cycloalkyl or Cl-8alkYlC3 _gCycloalkyl .
It will be understood that the alkylcycloalXyl, alkylphenyl, alkenylphenyl and alkynylphenyl groups are linked to the piperidine nitrogen atom via the alkyl, alkenyl and alkynyl moieties respectively.
Preferably R is Cl_8alkyl(phenyl)p in which p is 0 or l, i.e. Cl_8al~yl, such as n-pentyl, or phenylCl_8alkyl such as phenylpropyl, or R is C2_8alkenyl(phenyl)p wherein p is l, such as cinnamyl.
lS Suitably, n is 0 to 6; preferably n is 0 to 3; most preferably n is l.
Suitably, m is 0 to 3; preferably m is 0 or l; most pre~erably m i5 O.
Suitably, A is a bond, oxygen, sulphur or NRl;
pre~erably A is oxygen or sulphur; most preferably A is oxygen. When A is oxygen n is preferably l and m is preferably O.
Suitably, Ar is optionally substituted aryl or heteroaryl; preferably Ar is optionally substituted aryl.
Suitable aryl groups include, for example, unsaturated monocyclic and unsaturated or partially saturated bicyclic ring systems of up to lO carbon atoms, such as, for example, phenyl, naphthyl and tetrahydronaphthyl. Preferred are optionally substituted phenyl rings.
Suitable substituted phenyl rings include, for WO92/0~01 (~ PCT/GB91/01339 example, phenyl :- ngs substituted by a Cl_2alkylene-dioxy group such ~s a 3,4-methylenedioxy group or by l to 3 substituents selected from halogen, Cl_4alkoxy, nitro, SCl_4alkyl, NR2R2 ~in which each R2 group 5 can be H or cl_4alkyl), OCF3~ Cl-6alkYl~
trifluoromethyl, CN, optionally substituted phenyl, optionally substituted phenylCl_4alkyl and optionally substituted phenylCl_4alkoxy. Preferred are phenyl rings substituted by one or two substituents, in particular, by a single halogen, trifluoromethyl, unsubstituted phenyl or unsubstituted phenylCl_4alkoxy group; or by two chloro atoms especially in the 3- and 4-positions of the phenyl ring.
Suitable optionally substituted phenylCl_4aIkyl groups include, for example benzyl. Suitable optionally substituted phenylCl_4alkoxy groups include, for example benzyloxy groups.
Suitable substituents for said optionally substituted phenyl, phenylCl_4alkyl and phenylCl_4alkoxy groups include for example halogen, Cl_4alkyl, Cl_4aLkoxy, nitro and trifluoromethyl groups.
Suitable heteroaryl rings include, for example, unsaturated monocyclic and unsaturated or partially saturated bicyclic ring systems of up to lO carbon atoms containing at least one heteroatom, such as pyridyl, thienyl, quinolinyl, tetrahydroquinolinyl and imidazolyl rings. The heteroaryl ring can be linked to the remainder of structure (I) via a carbon atom or via a hetero atom, e.g. a nitrogen atom.
Suitable substituents for said heteroaryl rings 3~ include, for example, l to 3 substituents selected from halogen, Cl_4alkyl and Cl_4alkoxy.
W092/0~01 2 B ~ ~ ~ 9 ~ PCTJGBgl/01339 Alkyl groups present in the compounds of structure (I), alone or as part of another group, can be straight or branched.
It will be appreciated that ~or use in medicine a salt of a compound (I) should be pharmaceutically acceptable. Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically acceptable inorganic or organic acid addition salts. Other non-pharmaceutically acceptable salts may be used for example as intermediates and are included within the scope of this invention.
Particular compounds of the invention include:
3-(4-fluorophenoxymethyl)-1-pentylpiperidine oxalate, 3-(3,4-methylenedioxyphenoxymethyl)-1-pentylpiperidine hydrochloride, 3-(3-tri~luoromethylphenoxymethyl)-1-pentylpiperidine hydrochloride, 3-(3-phenylphenoxymethyl)-1-pentylpiperidine oxalate, 3-(2-phenylphenoxymethyl)-1-pentylpiperidine oxalate, 3-(4-phenylphenoxymethyl)-1-pentylpiperidine oxalate, 3-(2-benzylphenoxymethyl)-1-pentylpiperidine oxalate, 3-(4-benzylphenoxymethyl)-1-pentylpiperidine hydrochloride, 3-(4-benzyloxyphenoxymethyl)-1-pentylpiperidine hydrochloride, l-cinnamyl-3-(3,4-dichlorophenoxymethyl)piperidine oxalate, 3-(4-iso-propylphenoxymethyl)-1-pentylpiperidine hydrochloride, and 3-(3,4-dichlorophenylaminomethyl)-1-pentylpiperidine dihydrochloride.
It will be appreciated that the compounds of structure (I) may contain one or more asymmetric centres, in particular at the 3-position of the piperidine ring.
Such compounds will exist as optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of 2 ~
WO92/0~01 PCT/GB91/01339 the two are included within the scope of the invention.
Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention.
The compounds of the present invention can be prepared by processes analogous to those known in the art. The present invention therefore provides in a further aspect, a process for the preparation of a compound of structure (I) which comprises:
(a) for compounds of structure (I) in which A is O, S or NRl, reaction of a compound of structure (II):
~ 2)nA ~
R (II) in which R and n are as described for structure (I) and Al is o, S or NRl, with a compound of structure L(CH2)mAr in which m and Ar are as described for structure (I), and L is a leaving group;
(b) for compounds of structure (I) in which A is O, S or NRl, reaction of a compound of structure (III):
WO92/0~01 2 0 8 ~ ~ 9 PCT~GB91/01339 ,~CH2 ) nLl (III) R
in which n and R are as described for structure (I) and Ll is a group displaceable by a nucleophile, with a compound of structure HAl(CH2)mAr where m and Ar are as described for structure (I) and Al is as described for structure (II); or (c) for compounds of structure (I) in which A is NRl, reduction of a compound of structure (IV) :
~ ,,-N (IV) R
in which R4 represents the group O
(c~2)nN(Rl)c(cH2)m-lAr or ~(CH2)n-1CN(Rl)(CH2)~Ar' and n, m, R and Ar are as described for structure (I);
(d) for compounds of structure (I) in which A is a bond, reaction of a compound of structure (V) :
.
WO92/02501 , 2 ~ 3 3 ~ 9 0 PCT/GBgl/0l339 ( 2)n+m L
~ / (V) R
(wherein R, Ll, m and n are as hereinbefore defined).
with a compound of structure XlAr in which Ar is as described for structure (I), and Xl is an alkali metal;
(8) introduction o~ the group R into a co~pound of formula (VI) :
(CH2)nA(CH2)mAr ,'^~ /
(VI) by reaction with a compound RL2, wherein L2 is a leaving group;
(f) Reduction of a compound of formula (VII) :
2 ~
(CH2)nA(CH2)mAr J (VII) COR
wherein R5 is Cl_7alkyl(phenyl)p, C2_7alkenyl(phenyl)p, C2 7alkynyl(phenyl)p or Cl_7alkylC3_8cycloalkyl;
tg) Reduction of a compound of structure (VIII):
~ (CH2)n~tCH2)mAr I (VIII) N~ J
R
wherein R, A, Ar m and n are as hereinbefore defined and ~ is a counter ion;
and optionally thereafter forming a salt.
In process (a) the reaction between a compound of structure (II) and a compound L(CH2)mAr can take place under conditions which depend on the nature of the group L. For example, when L is halogen or a sulphonic acid residue such as a tosylate or mesylate, the reaction is carried out under standard conditions in a solvent, optionally in the presence of a base. When a fluoro-substituted aryl compound F-Ar is employed in WO92/0~01 ~ 8 ~ ~ 9 0 PCT/GB91/01339 _ g _ process (a), the reaction is effected in the presence of a strong base such as sodium hydride, and in an inert organic solvent such as dimethylformamide. Preferably the aryl group is substituted by an activating group such as CF3 or N02.
The reaction between a compound of structure (III) and a compound of structure HAl(CH2)mAr can take place under conditions which depend on the nature of and A. For example when Ll is hydroxy, m is 0 and Al is oxygen or sulphur the reaction is carried out in the presence of diethyl azodicarboxylate and triphenyl phosphine. Such a reaction is known as the Mitsunobu reaction (as described in Synthesis 1981, 1).
Alternatively the leaving group Ll may be for example a halogen atom or a sulphonyloxy group eg. methane-sulphonyloxy or p-toluene sulphonyloxy. In this case the reaction may be effected in the presence or absence of solvent and at temperature in the range 0 to 200C.
The reduction of a c~ound of structure (IV) can be effected by methods known in the art, for example using a reducing agent such as lithium aluminium hydride.
Conveniently a compound of structure (IV) can be prepared (for example as described below) and reduced in a 'one-pot' reaction, without isolation of compound (IV) itself.
The reaction between a compound of structure (V) and a compound of struc--~re Xl~r can take place under standard conditions known to those skilled in the art for the formation of carbon-carbon bonds.
The reaction of a compound of structure (VI) with RL2 according to process (e) may be effected in conventional manner, for example in an organic solvent, such as dimethyl formamide. The leaving group L2 may be for example a halide such as bromide or chloride, an acyloxy group such as acetoxy or chloroacetoxy or a WO92/02501 , PCT/GB91/01339 2~8l~9~
sulphonyloxy group such as methanesulphonyloxy or p-toluenesulphonyloxy. When L2 is a halide the reaction is preferably carried out in the presence of a weak base such as potassium carbonate, and when L2 is sulphonyloxy, a strong base such as sodium hydride or potassium t-butoxide may be employed.
Reduction of a compound of formula (VII) may be effected using standard reducing agents such as lithium aluminium hydride.
Reduction of a compound of formula ~VIII) may be effected ~or example by hydrogenation, using a noble metal catalyst such as platinum, palladium or platinum oxide, suitably in a solvent such as an alcohol eg.
ethanol.
The compounds o~ structure (II) can be prepared from the corresponding compounds in which R is hydrogen, by alkylation under standard conditions. For example, compounds of structure (II) in which R is n-pentyl can be prepared from the corresponding precursor in which R is hydrogen by reaction with an n-pentylhalide such as n-pentyl bromide in a suitable solvent, such as methyl ethyl ketone, or a Cl_4alkanol such as ethanol, in the presence of a base, such as potassium carbonate, or dimethylformamide in the presence of an iodoalkane.
The corresponding compounds of structure (II) in which R is hydrogen are available commercially, known in the literature or can be prepared by standard techniques;
for example by reduction of the corresponding 3-hydroxy-alkylpyridine.
Alternatively, the compounds of structure (II) in which Al is oxygen can be prepared by reduction of a compound of structure (IX):
W092/0250l 2 ~ 9 ~ PCTtGBg1/0l339 2 ) nOH
~ J (IX) S ~N X
R
in which R and n are as described for structure (I) and X~ is a counter ion.
Compounds of structure (III) wherein Ll is OH can be prepared as described for compounds of structure (II), and compounds o~ structure (III) wherein Ll is a halogen atom, or a mesyloxy or tosyloxy group can be prepared fr the corresponding alcohol in conventional manner.
Compounds of structure (IV) wherein R4 is a group o -(CH2)nN(Rl)C(CH2)m_lAr can be prepared by reacting a compound of structure (II) wherein Al represents NRl with an acylating agent corresponding to the group -(CH2)mAr, for example an acid chloride cloc(cH2)m-lAr-Compounds of structure (IV) wherein R4 is a group o -(CH2)n_lCN(Rl)(CH2)mAr may be prepared for example by reaction of a corresponding compound wherein R4 represents -(CH2)n_lCO2H or an activated derivative thereof such as an acid halide, ester or anhydride, with an amine of formula HN(Rl)(CH2)m Ar. It will be appreciated that when the acid itself is employed, reaction with the amine should be effected in WO92/0~01 PCT/GB9t/01339 2~4~
the presence of a coupling agent. The carboxylic acid may itself be prepared for example by oxidation of the corresponding alcohol, ie. a compound of structure (II) wherein Al is oxygen.
Compounds of structure (Y) may be prepared in analogous manner to compounds of structure (III); where necessary the chain length may be increased using methods well known in the art.
Compounds of structure (VI) may be prepared for example according to any of processes (a) to (d) above, using intermediates analogous to structures (II) to (IV) wherein R is replaced by an N-protecting group, which is subsequently removed by methods well known in the art.
Suitable protecting groups include aralkyl groups such as benzyl, diphenylmethyl or triphenylmethyl and acyl groups such as acetyl, trifluoroacetyl, benzoyl, methoxycarbonyl, ethoxycarbonyl, or benzyloxycarbonyl.
An aralkyl group such as benzyl may be cleaved by hydrogenolysis, and an acyl group such as benzoyl may be cleaved by hydrolysis. It will be appreciated that where the N-protecting group is aralkyl, the compound is of structure (I) and this reaction sequence thus provides a means of converting one compound of formula (I) into a different compound of formula (I).
A compound of formula (VII) may be prepared by reaction of a compound of formula (VI) with an appropriate acid derivative for example an acid chloride, or anhydride.
A compound of structure (VIII) may be prepared using the general methods described in processes (a) to (e) above.
.
W092/0~01 PCT/GB91/01339 2~d9~
When compounds of structure (I) are obtained as mixtures of enantiomers, these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column.
The compounds of the invention have been found to exhibit high calcium influx blocking activity and as such are expected to be of use in therapy in treating lo conditions and diseases related to an accumulation of calcium in the brain cells of mammals, in particular humans. For example, the compounds are expected to be of use in the treatment of anoxia, ischaemia including ~or example stroke, migraine, epilepsy, traumatic head in~ury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, and drug addiction withdrawal such as ethanol addiction withdrawal.
In a further aspect of the invention there is therefore provided a method of treatment of conditions or diseases caused or exacerbated by the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of structure (I) or a pharmaceutically acceptable salt thereof. In addition, the present invention also provides a method of treatment W092/02501 ~ ~ PCT/GB91/0133g of anoxia, ischaemia including for example stroke, migraine, epilepsy, traumatic head injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, and drug addiction withdrawal such as ethanol addiction withdrawal, which comprises administeriny to a subject in need thereof, an effective amount of a compound of structure (I) or a pharmaceutically acceptable salt thereo~.
In therapeutic use, the compounds of the present invention are usually administered in a standard pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical lS compositions comprising a compound of structure (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
The compounds o~ structure (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions~or-em~lsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
Examples of such carriers include magnesium stearate, WO92/02501 2 ~ 3 ~ ~ 9 ~ PCT/GB91/01339 starch, lactose, sucrose and cellulose.
A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
Compounds of the invention may also be administered parenterally, by bolus injection or continuous infusion. Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile agueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
Preferably the composition is in unit dose form such as a tablet or capsule.
Each dosage unit for oral administration contains preferably from l to 250 mg (and for parenteral administration contains preferably from O.l to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the ~ree bac-.
The daily dosage regimen for an adult patient may be, for example, an oral dose of between l ~g and 500 mg, preferably between l mg and 250 mg, eg. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of W092/0 01 ~ ~ 9 ~ PCT/GB91/01339 between O.l mg and lO0 mg, preferably between O.l mg and 60 mg, eg. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered l to 4 times per day. Alternatively the compounds of the invention may be administered by continuou~ intravenous infusion, preferably at a dose of up to lOOmg per day.
Suitably the co~pounds will be administered for a period of continuous therapy, for examp}e for a week or more.
W092/0~01 2 ~ 9 0 PCT/GB9l/01339 DATA
Ca~+ Current Measurement Cell preparations Sensory neurons from dorsal root ganglia were dissociated from 1 day old rat pups (Forda et al, Developmental Brain Research, 22 (1985), 55-65). Cells were plated out onto qlass coverslips and used within 3 days to permit e~fective voltage clamp o~ Ca2+ currents.
Solutions The pipette (internal solution) contained in mM:
CsCl, 130; HEPES, 10; EGTA, 10; MgC12, 4; ATP, 2;
buffered to pH 7.2 with CsOH~
Cells were bathed in a normal ~yrodes solut~on be~ore establishment o~ whole cell record~ng when the bathing solution was changed to one allowing isolation of Ca2+ currents.
The external solution-~or recording Ca2+ channel currents contained in mM: BaC12, lo; TEA-Cl, 130;
glucose, 10; HEPES, 10; NgC12, 1; buffered to pH 7.3 with TEA-OH. Barium was used as the charge carrier as this assists in current isolation and calcium dependent inactivation of current is avoided.
Compounds were dissolved in DMSO to make a 20 mM
stock solution. At the drug concentration used the vehicle (0.1%) had no significant effect on Ca2+
currents.
All experiments were performed at 21 to 24C.
Whole cell currents were recorded using List EPC-7 amplifiers and stored, digitised for later analysis using W092~0~ ~ ~ 9 ~ PCT/GB91/01339 PC based software similar to that described previously (Benham ~ Tsien, Journal of Physiology (1988), 404, 767-784).
RESULTS
Ca2+ currents Peak voltage gated Ca2+ channel currents of up to 10 nA ~rom dorsal root ganglion neurons were recorded using 10 mM Ba2+ as charge carrier. Currents were evoked ~rom arholding potential of -80 mV to a test potential of 0 or +10 mV every 15 seconds. This test potential was at the peak of the current voltage relationship and assessing block at this point reduced any errors due to dri~ting holding potential. Some cells showed slow rundown o~ current as is commonly seen when recording ca2+ currents. The rundown rate was measured in control conditions and extrapolated through the time o~ drug application to derive a control value to relate the drug a~fected current to. Block by 20 ~M
drug was assessed 3 minutes a~ter drug application.
Compounds o~ the invention gave percentage inhibition o~ plateau Ca2+ current in the range 30 to 100%.
W092/0~01 2 ~ ~ 3 ~ 9 0 PCT/GB91/01339 PHARMACEUTICAL FORMULATIONS
l. Formulation for intravenous infusion Compound of structure (I) O.l - 60 mg Sodium hydroxide/hydrochloric acid to pH ca 7 polyethylene glycol O - 30 ml propylene glycol O - 30 ml alcohol O - lO ml water to lOO ml 2. Formulation for bolus iniection Compound of structure ~I) O.l - 60 mg 15 sodium hydroxide or hydrochloric acid to pH ca 7 polyethylene glycol O - 2.5 ml alcohol O - 2.5 ml water to 5 ml A toxicity adjusting agent eg. sodium chloride, dextrose or mannitol may also be added.
3. Tablet for ora~ administration ma/tablet Compound of structure (I) 25 lactose lS3 starch 33 crospo~idone 12 microcrystalline cellulose 30 magnesium stearate 2 WO92/0~01 , PCT/GB9l/01339 2 ~
EXAMPLES
Intermediate PreParations (i) 3-(Hvdroxvmethvl)-l-PentvlPiPeridine A mixture of 3-~hydroxymethyl)piperidine (20g), 1-bromopentane (26.28g), potassium carbonate (24g) and ethanol ~400ml) was heated at reflux for 4 days. The solution was filtered, and the solvent removed under reduced prçssure. The residue was treated with acetone, filtered, the solvent removed and the resulting oil was distilled under reduced pre~sure to give the title compound as an o~ 24.63g, b.p. 103-104C @ 0.3mmHg.) (ii)3-(Hvdroxvmethvl)-l-ProPvlDiPeridine A mixture of 3-~hydroxymethyl)piperidine ~20g), 1-bromopropane (21.4g), potassium carbonate (24g) and ethanol (400ml) was heated at reflux for 1 days. The solution was filtered, and the solvent removed under reduced pressure. The residue was treated with acetone, filtered, the solvent removed and the resulting oil distilled under reduced pressure to give the title compound as an oil. (18.21 g, b.p. 101-103C Q 0.2mmHg.) (iii) l-Cinnamvl-3-(hvdroxYmethYl)~iPeridine A mixture of 3-(hydroxymethyl)piperidine (28g), cinnamyl bromide (47.91g), potassium carbonate (33.6g) and ethanol W092/02501 2 ~ PCT/GB9t/01339 ~300ml) was heated at reflux for 2 days. The solution was filtered, and the solvent removed under reduced pressure.
The residue was distilled under reduced pressure to give the title compound as an oil. (24.63g, b.p. 164-168 C @
0.3mmHg.) Found: C, 77.59; H, 9.18; N, 5.94%
(C15H21NO) requires: C, 77.88; H, 9.15; N, 6.05%
10 (iv) 3-Methanesul~honvloxvmethvl-l-PentvlPiPeridine hVdrochloride Methanesulphonyl chloride ~5.8ml) in dichloromethane ~20ml~ was added to a solution of 3-hydroxymethyl-1-pentylpiperidine (lOg) in dichloromethane (20ml). Themixture was stirred for 18 hours, treated with hydrogen chloride in ether and recrystallised from ethylacetate to give the title compound (13.2g) m.p. 99-101C
(v) 3-(3-HvdroxvProPvl)-l-PentvlPvridinium bromide A solution of 3-(3-hydroxypropyl)pyridine (20g), 1-bromopentane (22.05g) and acetone (250ml) was refluxed for 72 hours, cooled and poured into diethylether (200ml).
The oil which precipitated was collected by decantation then washed by decantation with diethyl ether (5 X lOOml) and dried at 50C (O.lmmHg) to give the title compound (42g)which was used without further purification.
(vi) 3-~3-HvdroxvProPvl)-l-pentvlpiPeridine W092/0250~j~t~ PCT/GB91/01339 A mixture of 3-(3-hydroxypropyl)-1-pentylpyridinium bromide ~42.g), platinum oxide (1.5g) and ethanol (350ml) was shaken under an atmosphere of hydrogen at 50 p.s.i.
for 1 hour. The mixture was filtered and the solvent S removed. The residue was dissolved in dilute sodium hydroxide (70ml) and extracted with dichloromethane (3 x 75ml). The organic extracts were combined, dried over magnesium sulphate and the solvent was removed to give the title compound as an oil (18.0g).
ExamPle 1 3-(4-FluoroPhenoxvmethYl)-l-PentvlPiperidine oxalate A solution of 3-(hydroxymethyl)-1-pentylpiperidine ~2.0g), 4-fluorophenol (1.21g) and triphenylphosphine (2.62g) in tetrahydrofuran (40ml) was treated with diethyl azodicarboxylate (1.74g) in tetrahydrofuran (lOml). The resulting solution was stirred at room temperature for 18 hours, the solvent was removed and the residue was chromatographed on silica gel eluted with methanol/dichloromethane. The resulting,,oil was dissolved in ethyl acetate (SOml) and treated with oxalic acid (0.62g). The precipitate was collected by filtration and recrystallised (methanol/ethyl acetate) to give the title compound (1.21g), m.p. 126 - 128C.
Found: C, 61.17; H, 7.79; N, 3.78; F 4.71%.
(C17H26FNO.C2H204.3H20) requires: C, 60.80; H, 7.60;
N, 3.70; F, 5.06%.
WO 92/02501 PCr/GB91/01339 xamPle 2 3- (3,4-MethYlenedioxYPhenoxvmethY~ -pentvlpiperidine hYdrochloride A solution of 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), sesamol (1.49g) and triphenylphosphine (2.62g) in tetrahydrofuran (50ml) was treated with diethyl azodicarboxylate (1.74g) in tetrahydrofuran (lOml~. The 10 resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with methanol/dichloromethane. The resulting oil was dissolved in ethyl acetate (50ml) and treated with ethereal hydrogen chloride. The precipitate 15 was collected by filtration and recrystallised (methanol/ethyl acetatel to give the title compound (l.Olg), m.p. 183 - 184C.
Found: C, 63.27; H, 8.22; N, 4.17; Cl, 10.37%.
(C18H27N03.HCl) requires: C, 63.25; H, 8.20; N, 4.10;
Cl, 10.40%.
ExamPle 3 25 3-(3-PhenYlPhenoxvmethvl)-l-PentYlpiperidine oxalate A solution of 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), 3-phenylphenol (1.70g) and triphenylphosphine (2.62g) in tetrahydrofuran (40ml) was treated with diethyl azodicarboxylate (1.66g) in tetrahydrofuran (50ml). The resulting solution was stirred at room temperature for 18 hours, the solvent was removed and the residue was W092/0~01 ~ PCT/&B91/01339 chromatographed on silica gel eluted with methanol/dichloromethane. The resulting oil (l.lg) was dissolved in ethyl acetate (SOml) and treated with oxalic acid (l.lequivalents). The precipitate was collected by filtration and recrystallised (methanol/ethyl acetate) to give the title compound ~0.8g), m.p. 148 - 14~C.
Found: C, 70.46; H, 7.80; N, 3.24%.
~C23H31NO.C2H204~ requires: C, 70.23; H, 7.78; N, 3.28%
Exam~le 4 3-(2-PhenYlphenox~methvl)-l-PentYlPiPeridine oxalate ~5 A 801ution of 3-~hydroxymethyl)-1-pentylpiperidine (2.0g), 2-phenylphenol ~1.70g) and triphenylphosphine ~2.62g) in tetrahydrofuran ~SOml) was treated with diethyl azodicarboxylate ~1.74g) in tetrahydrofuran (lOml). The resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with methanol/dichloromethane. The resulting oil was dissolved in ethyl acetate (50ml) and treated with oxalic acid (0.9g). The precipitate was collected by filtration and recrystallised (methanol/ethyl acetate) to give the title compound (l.lOg), m.p. 99 - 101C.
Found: C, 70.00; H, 7.97; N, 3.28%
(C23H31NO.C2H204) requires: C, 70.23; H, 7.78; N, 3.28%
W092/0~01 , PCT/GB91~01339 2 3 ~ a ExamPle 5 3-(4-BenzvloxvPhenoxvmethvl)-l-PentYlPiperidine hvdrochloride A solution of 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), 4-benzyloxyphenol ~2.0g) and triphenylphosphine ~2.62g) in tetrahydrofuran ~50ml) was treated with diethyl azodicarboxylate ~1.74g) in tetrahydrofuran (lOml). The resulting solution was stirred at room temperature for 18 hours, the solvent remo~ed and the residue chromatographed on silica gel eluted with methanol/dichloromethane. The resultlng oil was dissol~ed ~n ethyl acetate and treated with hydrogen chloride in diethyl ether. The precipitate was collected by f~ltratlon and recrystallised ~methanol/ethyl acetate) to give the title compound (0.5g), m.p. 149 - 150C.
Found: C, 71.56; H, 8.71; N, 3.43; Cl, 8.57%
~C24H33N02.HCl) requires: C, 71.35; H, 8.48; N, 3.47;
Cl, 8.78%
ExamPle 6 3-(4-9enzvlPhenoxvmethYl)-l-PentvlPiperidine hvdrochloride The title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-pentylpiperidine ~2.0g), 4-hydroxydiphenylmethane (1.84g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride ga~e WO92/0~01 PCT~GB9t/01339 ~3~ 3 a white solid which was recrystallised from methanol/ethyl acetate (O.Slg), m.p. 169 - 171C.
Found: C, 74.38; H, 8.96; N, 3.68; Cl, 8.22%
~C24H33NO.HCl) requires: C, 74.30; H, 8.83; N, 3.61;
Cl, 9.16~
ExamPle 7 3-~3-TrifluoromethvlPhenoxvmethvl)-l-~entvlPiPeridine hvdrochloride The title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-pentylplperidine (1.85g), 3-trifluoromethylphenol (1.62g), triphenylphosphine ~2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate (0.41g), m.p. 165C.
Found: C, 59.04; H, 7.40; N, 3.91; Cl, 9.67%
(C18H26F3NO.HCl) requires: C, 59.0; H, 7.4; N, 3.8;
Cl, 9.7%
ExamPle 8 3-(4-Nitrophenoxvmethvl)-l-PentvlPiPeridine hvdrochloride The title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-pentylpiperidine (1.85g), 4-nitrophenol (1.39g), triphenylphosphine ~2.62g) and diethyl azodicarboxylate W092/0250l PCT/GB9l/01339 23(3~d9~
~1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate (0.13g), m.p. 220C.
S Found: C, 59.22; H, 7.96; N, 8.08; Cl, 10.31%
(C17H26N203.HCl) requires: C, 59.55; H, 7.94; N, 8.17;
Cl, 10.35%
ExamPle 9 3-~4-PhenYlPhenoxvmethvl)-l-PentvlPi~eridine oxalate The title compound was prepared in a similar manner to example 5 starting from 3-~hydroxymethyl)-1-pentyl-piperidine (2.0g), 4-phenylphenol ~1.70g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (0.60g), m.p. 173.5 - 174C.
Found: C, 70.17; H, 7.74; N, 3.50%
(C23H31NO.C2H204) requires: C, 70.23; H, 7.78; N, 3.28%
ExamPle 10 3-(2-BenzYlPhenoxvmethYl)-l-Pentylpiperidine oxalate The title compound was prepared in a similar manner to example 5 starting from 3-hydroxymethyl-1-pentylpiperidine (2.0g), 2-hydroxydiphenylmethane (1.84g), - triphenylphosphine ~2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a WO 92/02501 PCr/GB91/01339 2~ o white solid which was recrystallised from methanol/ethyl acetate ~0.260g), m.p. 120C.
Found: C, 70.21; H, 7.99; N, 3.20%
~C24H33NO.C2H204Ø25H20) requires: C, 69.94; H, 7.96;
N, 3.14%
ExamPle 1 1 10 3-(4-ChloroPhenoxvmethvl)-l-PentvlPiPeridine oxalate The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-penty}piperidine (2.0g), 4-chlorophenol (1.28g), triphenylphosphine ~2.62g) and 15 dlethyl azodlcarboxylate ~1.74g). Treating the product wlth oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate ~0.82g), m.p. 140C.
Found: C, 59.27; H, 7.26; N, 3.80; Cl, 8.93%
~C17H26ClNO.C2H204) requires: C, 59.14; H, 7.31; N, 3.63;
Cl, 9.1996 Examl~le 12 3-(4-Cvano~henoxvmethYl)-l-~entvlPi~eridine oxalate The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine ~2.0g), 4-cyanophenol ~1.19g), triphenylphosphine ~2.62g) and diethyl azodicarboxylate ~1.74gt. Treating the product with oxalic acid gave a white solid which was WO92/0~01 PCT/GB91/01339 9 ~
recrystallised from methanol/ethyl acetate (0.79g), m.p. 104C.
Found: C, 63.83; H, 7.59; N, 7.47%
(C18H26N2O~C2H2O4) requires: C, 63.81; H, 7.50; N, 7.44%
Exam~le 13 3-~henoxvmethvl-1-~entvlPi~eridine oxalate The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2 Og), phenol (0.94g), triphenylphosphine (2.62g) and diethyL
azodlcarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (1.02g), m.p. 144.5C.
Found: C, 65.15; H, 8.43; N, 4.02%
~C17H27NO.C2H2O4) requires: C, 64.93; H, 8.32; N, 3.99%
ExamPle 14 3-(4-Fluorobenzvloxvmethvl)-1-PentvlPiPeridine oxalate A solution of 3-hydroxymethyl-1-pentylpiperidine (3.0g) in dimethylformamide (30 ml) was treated with sodium hydride (0.0162 mole) and then stirred for 0.5 hour when 4-fluorobenzyl chloride (2.35g) was added. The mixture was stirred for 2 days and the solvent removed. Water (100 ml) and dichloromethane (100 ml) were added and the organic layer was separated, washed with saturated sodium chloride (150 ml) and dried over magnesium sulphate. The W092/0~01 PCT/GB9l/01339 2~3~ 30 solvent was removed and the residue chromatographed on silica gel using methanol/d$chloromethane as eluent. The resulting oil was dissolved in ethyl acetate and treated with oxalic acid (1.1 mole equivalent). The precipitate was collected by filtration and recrystallised ~methanol/ethyl acetate) to give the title compound ~1.2g), m.p. 126 - 127C.
Found: C, 62.64; H, 7.97; N, 3.66%.
~C18H28FNO.C2H204) requires: C, 62.64; H, 7.89; N, 3.65%
ExamPle 15 3-~3,4-Meth~lenedioxvPhenoxYmethYl)-l-Propylpiperidine hYdrochlorlde The title compound was prepared in a similar manner to example 5 starting from 3-~hydroxymethyl)-1-propyl-piperidine ~1.57g), sesamol ~1.38g), triphenylphosphine ~2.62g~ and diethyl azodicarboxylate ~1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate ~0.39g), m.p. 154C.
Found: C, 59.14; H, 7.63; N, 4.62; Cl, 10.77%
~C16H23N03.HCl.O.SH20) requires: C, 59.47; H, 7.74;
N, 4.34; Cl, 10.84%
WO92/02501 2 ~ ~ ~ d ~ V PCTJGB9l/01339 ~xamPle 16 l-Cinnamvl-3-(3,4-dichloroPhenoxvmethvl)PiPeridine oxalate The title compound was prepared in a similar manner to example 1 from 1-cinnamyl-3-hydroxymethylpiperidine ~2.00g), 3,4-dichlorophenol (1.41g), triphenylphosphine (2.27g) and diethyl azodicarboxylate (l.Slg). Treating the product with oxalic acid in ethyl acetate gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (1.27g), m.p.206C.
Found: C, 59.37; H, 5.46; N, 3.16; Cl, 15.16~
(C21H23C12NO~C2H2O4) requires C, 59.24; H, 5.40; N, 3.00;
Cl, 15.16%
ExamPle 17 l-Cinnamvl-3-~4-fluoroPhenoxvmethvlt~iPeridine oxalate The title compound was prepared in a similar manner to example 1 from 1-cinnamyl-3-hydroxymethylpiperidine (2.00g), 4-fluorophenol (0.971g), triphenylphosphine (2.27g) and diethyl azodicarboxylate (1.51g). Treating the product with oxalic acid in ethyl acetate gave a white solid which was recrystallised ~rom ethyl acetate/methanol to give the title compound as a white crystalline solid (0.7g), m.p.123C.
Found: C, 66.51; H, 6.31; N, 3.44%
(C2lH24FNo~c2H2o4) requires: C, 66.49; H, 6.31; N, 3.37 W092/0~01 PCT/GB91/01339 2 ~
ExamPle 18 3-(3,4-Dichloro~henoxYmethYl)-l-PentYlpi~eridine hvdrochlorlde The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.00g), 3,4-dichlorophenol (1.63g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (l.lOg), m.p.188-190C.
Found: C, 55.92; H, 7.18; N, 3.86; Cl , 9.64%
~C17H25C12NO~HCl) requlres: C, 55.67; H, 7.15; N, 3.82;
Cl-, 9.68%
ExamPle 1 9 3-(4-iso-ProPYlPhenoxvmethYl)-l-pentvlpiperidine hvdrochloride The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.00g), 4-iso-propylphenol (1.36g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to gi~e the title compound as a white crystalline solid (0.18g), m.p.172-174C.
Found: C, 70.41; H, 9.95; N, 4.34%
2 ~ 3 l~
(C20H33NO.HCl) requires: C, 70.66; H, 10.08; N, 4.12%
ExamPle 20 3-(3-iso-Pro~vlPhenoxvmethvl)-l-Pentvl~iPeridine hYdrochloride The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (1.5g), 3-iso-propylphenol (l.lg), triphenylphosphine (2.12g) and diethyl azodicarboxylate (1.41g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.8g), m.p.138-140C.
Found: C,-69.89; H, 9.91; N, 4.io; Cl , 10.33%
(C2oH33NO.HClØ25 H2O) requires: C, 69.74; H, 9.95; N, 4.07; Cl-, 10.29 ExamPle 21 3-(3-tert-ButvlPhenoxvmethvl)-l-PentvlPiPeridine hvdrochloride The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-penty}piperidine (1.50g), 3-tert-butylphenol (1.22g), triphenylphosphine (2.12g) and diethyl azodicarboxylate (1.41g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the - 30 title compound as a white crystalline solid (1.035g), m.p.185-187C.
Found: C, 71.39; H, 10.33; N, 4.09; Cl, 9.92%
~C21H35NO.HCl) requires: C, 71.26; H, 10.25; N, 3.96;
Cl,10.02%
ExamPle 22 3-(4-Fluorobenzvlaminomethvl)-PentvlPiPeridine dihvdrochloride A mixture of 4-fluorobenzylamine ~2.49g) and 3-methanesulphonyloxymethyl-l-pentylpiperidine hydrochloride (2g) was heated at 150C for 2.5 hours. The mixture was dissolved in dichloromethane and the dichloromethane solution washed with dilute sodium hydroxide solution, drled over sodium sulphate and the solvent removed. The residue was chromatographed on silica gel with d~chloromethane - methanol as eluent and treated with hydrogen chloride in ether to give a solid.
Recrystallisation from ethyl acetate gave the title compound (0.92g), m.p. 207-209C.
Found: C, 58.12; H, 8.55; N, 7.67; Cl, 19.41%
(C18H29FN2.2HClØ3H20) requires: C, 58.26; H, 8.57; N, 7.54; Cl, 19.09%
ExamPle 23 3-(4-FluoroPhenvlaminomethvl~-PentvlPiPeridine dihvdrochloride Substituting 4-fluoroaniline for 4-fluorobenzylamine (9.12g) in example 22 gave the title compound (0.593g) as a white microcrystaline solid. m.p. 196-198C
WO g2/02501 2 ~ 3 ~ PCr/GBgl/0133g Found: C, 56.77; H, 8.12; N, 7.83; Cl, 19.63%
(C17H27FN2.2HC1Ø5H20) requires: C, 56.66; H, 8.39; N, 7.77; Cl, 19.68%
Exam~le 24 3-(3,4-DichloroPhenYlaminomethvl)-PentvlPiPeridine dihvdrochloride Substituting 3,4-dichloroaniline for 4-fluorobenzylamine (4.04g) in example 22 gave the title compound (0.38g) as a white microcrystaline solid. m.p. 185-187C
Found: C, 50.99; H, 7.02; N, 6.99%
~C17H26C12N2.2HCl) requires: C, 50.76; H, 7.027 N, 6.96 ExamPle 25 3-(4-tert-ButvlPhenoxYmethvl)-1-PentvlPiPeridine hvdrochloride The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (l.SOg), 4-tert-butylphenol (1.22g), triphenylphosphine (2.12g) and diethyl azodicarboxylate (1.41g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.205g), m.p.197-199C.
Found: C, 70.98; H, 10.21; N, 4.00; Cl, 9.82%
23~9~
tC21H35NO.HCl) requires: C, 71.26; H, 10.25; N, 3.96;
Cl,10.02%
~xamPle 26 3- r 3-(4-Fluoro~henoxv)ProPvll-l-PentvlPiperidine oxalate The title compound was prepared in a similar manner to example 1 from 1-pentyl-3-(3-hydroxypropyl)piperidine (2.13g), 4-fluorophenol tl.l2g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate tl.lOg), m.p.
115 - 118C.
1~ Found: C, 63.53; H, 8.11; N, 3.80~
tClgH30FNO.C2H204) requires: C, 63.4B; H, 8.06; N, 3.53%
ExamPle 27 3-r3-(3,4-DichloroPhenoxv)~roPvll-l-pentylpiperidine oxalate The title compound was prepared in a similar manner to example 1 from 1-pentyl-3-t3-hydroxypropyl)piperidine t2.13g), 3,4-dichlorophenol tl.63g), triphenylphosphine ~2.62g) and diethyl azodicarboxylate tl.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate tO.Sg), m.p.
127-130C.
Found: C, 56.35; H, 6.90; N, 3.25%
tClgH2gC12NO.C2H204) requires: C, 56.25; H, 6.97; N, 3.12%
WO92/02501 2 ~ 8 3 ~ Pcr/GBgliol339 ExamPle 28 a) ~-)-3-(4-BenzYloxvPhenoxvmethYl)-l-pentvlPiPeridine b) ~ 3-~4-BenzvloxYPhenoxYmethYl)-l-~entvlplperidine The product from example 5 (55mg) was partitioned between diethyl ether and dilute sodium bicarbonate solution. The ether phase was separated, dried and the solvent removed.
The residue was chromatographed on a Chiralcel OJ h.p.l.c.
chromatography column using ethanol/hexane as eluent. The two enant, ~ers were collected. The (-) enantiomer being eluted first. Yield (8.0mg) rotation (-1.38 @ 22C in methanol). The second peak gave the (+) enantiomer, yield ~7.2mg) rotation ~1.24 @ 22C in methanol).
ExamPle 29 3-(3,4-DichlorobenzvlaminomethYl)-l-PentvlPiPeridine dihvdrochloride Substituting 3,4-dichlorobenzylamine for 4-fluorobenzylamine (0.587g) in example 22 gave the title compound (0.46g) as a white microcrystaline solid. m.p.
Found: C, 51.55; H, 7.09; N, 6.73; Cl, 16.85%
(C18H28C12N2.2HCl) requires: C, 51.94; H, 7.26; N, 6.73;
Cl, 17.04%
It will be understood that the alkylcycloalXyl, alkylphenyl, alkenylphenyl and alkynylphenyl groups are linked to the piperidine nitrogen atom via the alkyl, alkenyl and alkynyl moieties respectively.
Preferably R is Cl_8alkyl(phenyl)p in which p is 0 or l, i.e. Cl_8al~yl, such as n-pentyl, or phenylCl_8alkyl such as phenylpropyl, or R is C2_8alkenyl(phenyl)p wherein p is l, such as cinnamyl.
lS Suitably, n is 0 to 6; preferably n is 0 to 3; most preferably n is l.
Suitably, m is 0 to 3; preferably m is 0 or l; most pre~erably m i5 O.
Suitably, A is a bond, oxygen, sulphur or NRl;
pre~erably A is oxygen or sulphur; most preferably A is oxygen. When A is oxygen n is preferably l and m is preferably O.
Suitably, Ar is optionally substituted aryl or heteroaryl; preferably Ar is optionally substituted aryl.
Suitable aryl groups include, for example, unsaturated monocyclic and unsaturated or partially saturated bicyclic ring systems of up to lO carbon atoms, such as, for example, phenyl, naphthyl and tetrahydronaphthyl. Preferred are optionally substituted phenyl rings.
Suitable substituted phenyl rings include, for WO92/0~01 (~ PCT/GB91/01339 example, phenyl :- ngs substituted by a Cl_2alkylene-dioxy group such ~s a 3,4-methylenedioxy group or by l to 3 substituents selected from halogen, Cl_4alkoxy, nitro, SCl_4alkyl, NR2R2 ~in which each R2 group 5 can be H or cl_4alkyl), OCF3~ Cl-6alkYl~
trifluoromethyl, CN, optionally substituted phenyl, optionally substituted phenylCl_4alkyl and optionally substituted phenylCl_4alkoxy. Preferred are phenyl rings substituted by one or two substituents, in particular, by a single halogen, trifluoromethyl, unsubstituted phenyl or unsubstituted phenylCl_4alkoxy group; or by two chloro atoms especially in the 3- and 4-positions of the phenyl ring.
Suitable optionally substituted phenylCl_4aIkyl groups include, for example benzyl. Suitable optionally substituted phenylCl_4alkoxy groups include, for example benzyloxy groups.
Suitable substituents for said optionally substituted phenyl, phenylCl_4alkyl and phenylCl_4alkoxy groups include for example halogen, Cl_4alkyl, Cl_4aLkoxy, nitro and trifluoromethyl groups.
Suitable heteroaryl rings include, for example, unsaturated monocyclic and unsaturated or partially saturated bicyclic ring systems of up to lO carbon atoms containing at least one heteroatom, such as pyridyl, thienyl, quinolinyl, tetrahydroquinolinyl and imidazolyl rings. The heteroaryl ring can be linked to the remainder of structure (I) via a carbon atom or via a hetero atom, e.g. a nitrogen atom.
Suitable substituents for said heteroaryl rings 3~ include, for example, l to 3 substituents selected from halogen, Cl_4alkyl and Cl_4alkoxy.
W092/0~01 2 B ~ ~ ~ 9 ~ PCTJGBgl/01339 Alkyl groups present in the compounds of structure (I), alone or as part of another group, can be straight or branched.
It will be appreciated that ~or use in medicine a salt of a compound (I) should be pharmaceutically acceptable. Examples of pharmaceutically acceptable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically acceptable inorganic or organic acid addition salts. Other non-pharmaceutically acceptable salts may be used for example as intermediates and are included within the scope of this invention.
Particular compounds of the invention include:
3-(4-fluorophenoxymethyl)-1-pentylpiperidine oxalate, 3-(3,4-methylenedioxyphenoxymethyl)-1-pentylpiperidine hydrochloride, 3-(3-tri~luoromethylphenoxymethyl)-1-pentylpiperidine hydrochloride, 3-(3-phenylphenoxymethyl)-1-pentylpiperidine oxalate, 3-(2-phenylphenoxymethyl)-1-pentylpiperidine oxalate, 3-(4-phenylphenoxymethyl)-1-pentylpiperidine oxalate, 3-(2-benzylphenoxymethyl)-1-pentylpiperidine oxalate, 3-(4-benzylphenoxymethyl)-1-pentylpiperidine hydrochloride, 3-(4-benzyloxyphenoxymethyl)-1-pentylpiperidine hydrochloride, l-cinnamyl-3-(3,4-dichlorophenoxymethyl)piperidine oxalate, 3-(4-iso-propylphenoxymethyl)-1-pentylpiperidine hydrochloride, and 3-(3,4-dichlorophenylaminomethyl)-1-pentylpiperidine dihydrochloride.
It will be appreciated that the compounds of structure (I) may contain one or more asymmetric centres, in particular at the 3-position of the piperidine ring.
Such compounds will exist as optical isomers (enantiomers). Both the pure enantiomers, racemic mixtures (50% of each enantiomer) and unequal mixtures of 2 ~
WO92/0~01 PCT/GB91/01339 the two are included within the scope of the invention.
Further, all diastereomeric forms possible (pure enantiomers and mixtures thereof) are within the scope of the invention.
The compounds of the present invention can be prepared by processes analogous to those known in the art. The present invention therefore provides in a further aspect, a process for the preparation of a compound of structure (I) which comprises:
(a) for compounds of structure (I) in which A is O, S or NRl, reaction of a compound of structure (II):
~ 2)nA ~
R (II) in which R and n are as described for structure (I) and Al is o, S or NRl, with a compound of structure L(CH2)mAr in which m and Ar are as described for structure (I), and L is a leaving group;
(b) for compounds of structure (I) in which A is O, S or NRl, reaction of a compound of structure (III):
WO92/0~01 2 0 8 ~ ~ 9 PCT~GB91/01339 ,~CH2 ) nLl (III) R
in which n and R are as described for structure (I) and Ll is a group displaceable by a nucleophile, with a compound of structure HAl(CH2)mAr where m and Ar are as described for structure (I) and Al is as described for structure (II); or (c) for compounds of structure (I) in which A is NRl, reduction of a compound of structure (IV) :
~ ,,-N (IV) R
in which R4 represents the group O
(c~2)nN(Rl)c(cH2)m-lAr or ~(CH2)n-1CN(Rl)(CH2)~Ar' and n, m, R and Ar are as described for structure (I);
(d) for compounds of structure (I) in which A is a bond, reaction of a compound of structure (V) :
.
WO92/02501 , 2 ~ 3 3 ~ 9 0 PCT/GBgl/0l339 ( 2)n+m L
~ / (V) R
(wherein R, Ll, m and n are as hereinbefore defined).
with a compound of structure XlAr in which Ar is as described for structure (I), and Xl is an alkali metal;
(8) introduction o~ the group R into a co~pound of formula (VI) :
(CH2)nA(CH2)mAr ,'^~ /
(VI) by reaction with a compound RL2, wherein L2 is a leaving group;
(f) Reduction of a compound of formula (VII) :
2 ~
(CH2)nA(CH2)mAr J (VII) COR
wherein R5 is Cl_7alkyl(phenyl)p, C2_7alkenyl(phenyl)p, C2 7alkynyl(phenyl)p or Cl_7alkylC3_8cycloalkyl;
tg) Reduction of a compound of structure (VIII):
~ (CH2)n~tCH2)mAr I (VIII) N~ J
R
wherein R, A, Ar m and n are as hereinbefore defined and ~ is a counter ion;
and optionally thereafter forming a salt.
In process (a) the reaction between a compound of structure (II) and a compound L(CH2)mAr can take place under conditions which depend on the nature of the group L. For example, when L is halogen or a sulphonic acid residue such as a tosylate or mesylate, the reaction is carried out under standard conditions in a solvent, optionally in the presence of a base. When a fluoro-substituted aryl compound F-Ar is employed in WO92/0~01 ~ 8 ~ ~ 9 0 PCT/GB91/01339 _ g _ process (a), the reaction is effected in the presence of a strong base such as sodium hydride, and in an inert organic solvent such as dimethylformamide. Preferably the aryl group is substituted by an activating group such as CF3 or N02.
The reaction between a compound of structure (III) and a compound of structure HAl(CH2)mAr can take place under conditions which depend on the nature of and A. For example when Ll is hydroxy, m is 0 and Al is oxygen or sulphur the reaction is carried out in the presence of diethyl azodicarboxylate and triphenyl phosphine. Such a reaction is known as the Mitsunobu reaction (as described in Synthesis 1981, 1).
Alternatively the leaving group Ll may be for example a halogen atom or a sulphonyloxy group eg. methane-sulphonyloxy or p-toluene sulphonyloxy. In this case the reaction may be effected in the presence or absence of solvent and at temperature in the range 0 to 200C.
The reduction of a c~ound of structure (IV) can be effected by methods known in the art, for example using a reducing agent such as lithium aluminium hydride.
Conveniently a compound of structure (IV) can be prepared (for example as described below) and reduced in a 'one-pot' reaction, without isolation of compound (IV) itself.
The reaction between a compound of structure (V) and a compound of struc--~re Xl~r can take place under standard conditions known to those skilled in the art for the formation of carbon-carbon bonds.
The reaction of a compound of structure (VI) with RL2 according to process (e) may be effected in conventional manner, for example in an organic solvent, such as dimethyl formamide. The leaving group L2 may be for example a halide such as bromide or chloride, an acyloxy group such as acetoxy or chloroacetoxy or a WO92/02501 , PCT/GB91/01339 2~8l~9~
sulphonyloxy group such as methanesulphonyloxy or p-toluenesulphonyloxy. When L2 is a halide the reaction is preferably carried out in the presence of a weak base such as potassium carbonate, and when L2 is sulphonyloxy, a strong base such as sodium hydride or potassium t-butoxide may be employed.
Reduction of a compound of formula (VII) may be effected using standard reducing agents such as lithium aluminium hydride.
Reduction of a compound of formula ~VIII) may be effected ~or example by hydrogenation, using a noble metal catalyst such as platinum, palladium or platinum oxide, suitably in a solvent such as an alcohol eg.
ethanol.
The compounds o~ structure (II) can be prepared from the corresponding compounds in which R is hydrogen, by alkylation under standard conditions. For example, compounds of structure (II) in which R is n-pentyl can be prepared from the corresponding precursor in which R is hydrogen by reaction with an n-pentylhalide such as n-pentyl bromide in a suitable solvent, such as methyl ethyl ketone, or a Cl_4alkanol such as ethanol, in the presence of a base, such as potassium carbonate, or dimethylformamide in the presence of an iodoalkane.
The corresponding compounds of structure (II) in which R is hydrogen are available commercially, known in the literature or can be prepared by standard techniques;
for example by reduction of the corresponding 3-hydroxy-alkylpyridine.
Alternatively, the compounds of structure (II) in which Al is oxygen can be prepared by reduction of a compound of structure (IX):
W092/0250l 2 ~ 9 ~ PCTtGBg1/0l339 2 ) nOH
~ J (IX) S ~N X
R
in which R and n are as described for structure (I) and X~ is a counter ion.
Compounds of structure (III) wherein Ll is OH can be prepared as described for compounds of structure (II), and compounds o~ structure (III) wherein Ll is a halogen atom, or a mesyloxy or tosyloxy group can be prepared fr the corresponding alcohol in conventional manner.
Compounds of structure (IV) wherein R4 is a group o -(CH2)nN(Rl)C(CH2)m_lAr can be prepared by reacting a compound of structure (II) wherein Al represents NRl with an acylating agent corresponding to the group -(CH2)mAr, for example an acid chloride cloc(cH2)m-lAr-Compounds of structure (IV) wherein R4 is a group o -(CH2)n_lCN(Rl)(CH2)mAr may be prepared for example by reaction of a corresponding compound wherein R4 represents -(CH2)n_lCO2H or an activated derivative thereof such as an acid halide, ester or anhydride, with an amine of formula HN(Rl)(CH2)m Ar. It will be appreciated that when the acid itself is employed, reaction with the amine should be effected in WO92/0~01 PCT/GB9t/01339 2~4~
the presence of a coupling agent. The carboxylic acid may itself be prepared for example by oxidation of the corresponding alcohol, ie. a compound of structure (II) wherein Al is oxygen.
Compounds of structure (Y) may be prepared in analogous manner to compounds of structure (III); where necessary the chain length may be increased using methods well known in the art.
Compounds of structure (VI) may be prepared for example according to any of processes (a) to (d) above, using intermediates analogous to structures (II) to (IV) wherein R is replaced by an N-protecting group, which is subsequently removed by methods well known in the art.
Suitable protecting groups include aralkyl groups such as benzyl, diphenylmethyl or triphenylmethyl and acyl groups such as acetyl, trifluoroacetyl, benzoyl, methoxycarbonyl, ethoxycarbonyl, or benzyloxycarbonyl.
An aralkyl group such as benzyl may be cleaved by hydrogenolysis, and an acyl group such as benzoyl may be cleaved by hydrolysis. It will be appreciated that where the N-protecting group is aralkyl, the compound is of structure (I) and this reaction sequence thus provides a means of converting one compound of formula (I) into a different compound of formula (I).
A compound of formula (VII) may be prepared by reaction of a compound of formula (VI) with an appropriate acid derivative for example an acid chloride, or anhydride.
A compound of structure (VIII) may be prepared using the general methods described in processes (a) to (e) above.
.
W092/0~01 PCT/GB91/01339 2~d9~
When compounds of structure (I) are obtained as mixtures of enantiomers, these may be separated by conventional methods such as crystallisation in the presence of a resolving agent, or chromatography, for example using a chiral HPLC column.
The compounds of the invention have been found to exhibit high calcium influx blocking activity and as such are expected to be of use in therapy in treating lo conditions and diseases related to an accumulation of calcium in the brain cells of mammals, in particular humans. For example, the compounds are expected to be of use in the treatment of anoxia, ischaemia including ~or example stroke, migraine, epilepsy, traumatic head in~ury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, and drug addiction withdrawal such as ethanol addiction withdrawal.
In a further aspect of the invention there is therefore provided a method of treatment of conditions or diseases caused or exacerbated by the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of structure (I) or a pharmaceutically acceptable salt thereof. In addition, the present invention also provides a method of treatment W092/02501 ~ ~ PCT/GB91/0133g of anoxia, ischaemia including for example stroke, migraine, epilepsy, traumatic head injury, AIDS-related dementia, neurodegenerative diseases such as Alzheimer's disease and age-related memory disorders, and drug addiction withdrawal such as ethanol addiction withdrawal, which comprises administeriny to a subject in need thereof, an effective amount of a compound of structure (I) or a pharmaceutically acceptable salt thereo~.
In therapeutic use, the compounds of the present invention are usually administered in a standard pharmaceutical composition. The present invention therefore provides in a further aspect pharmaceutical lS compositions comprising a compound of structure (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
The compounds o~ structure (I) and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions~or-em~lsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations.
Examples of such carriers include magnesium stearate, WO92/02501 2 ~ 3 ~ ~ 9 ~ PCT/GB91/01339 starch, lactose, sucrose and cellulose.
A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
Compounds of the invention may also be administered parenterally, by bolus injection or continuous infusion. Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile agueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
Preferably the composition is in unit dose form such as a tablet or capsule.
Each dosage unit for oral administration contains preferably from l to 250 mg (and for parenteral administration contains preferably from O.l to 60 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the ~ree bac-.
The daily dosage regimen for an adult patient may be, for example, an oral dose of between l ~g and 500 mg, preferably between l mg and 250 mg, eg. 5 to 200 mg or an intravenous, subcutaneous, or intramuscular dose of W092/0 01 ~ ~ 9 ~ PCT/GB91/01339 between O.l mg and lO0 mg, preferably between O.l mg and 60 mg, eg. 1 to 40 mg of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered l to 4 times per day. Alternatively the compounds of the invention may be administered by continuou~ intravenous infusion, preferably at a dose of up to lOOmg per day.
Suitably the co~pounds will be administered for a period of continuous therapy, for examp}e for a week or more.
W092/0~01 2 ~ 9 0 PCT/GB9l/01339 DATA
Ca~+ Current Measurement Cell preparations Sensory neurons from dorsal root ganglia were dissociated from 1 day old rat pups (Forda et al, Developmental Brain Research, 22 (1985), 55-65). Cells were plated out onto qlass coverslips and used within 3 days to permit e~fective voltage clamp o~ Ca2+ currents.
Solutions The pipette (internal solution) contained in mM:
CsCl, 130; HEPES, 10; EGTA, 10; MgC12, 4; ATP, 2;
buffered to pH 7.2 with CsOH~
Cells were bathed in a normal ~yrodes solut~on be~ore establishment o~ whole cell record~ng when the bathing solution was changed to one allowing isolation of Ca2+ currents.
The external solution-~or recording Ca2+ channel currents contained in mM: BaC12, lo; TEA-Cl, 130;
glucose, 10; HEPES, 10; NgC12, 1; buffered to pH 7.3 with TEA-OH. Barium was used as the charge carrier as this assists in current isolation and calcium dependent inactivation of current is avoided.
Compounds were dissolved in DMSO to make a 20 mM
stock solution. At the drug concentration used the vehicle (0.1%) had no significant effect on Ca2+
currents.
All experiments were performed at 21 to 24C.
Whole cell currents were recorded using List EPC-7 amplifiers and stored, digitised for later analysis using W092~0~ ~ ~ 9 ~ PCT/GB91/01339 PC based software similar to that described previously (Benham ~ Tsien, Journal of Physiology (1988), 404, 767-784).
RESULTS
Ca2+ currents Peak voltage gated Ca2+ channel currents of up to 10 nA ~rom dorsal root ganglion neurons were recorded using 10 mM Ba2+ as charge carrier. Currents were evoked ~rom arholding potential of -80 mV to a test potential of 0 or +10 mV every 15 seconds. This test potential was at the peak of the current voltage relationship and assessing block at this point reduced any errors due to dri~ting holding potential. Some cells showed slow rundown o~ current as is commonly seen when recording ca2+ currents. The rundown rate was measured in control conditions and extrapolated through the time o~ drug application to derive a control value to relate the drug a~fected current to. Block by 20 ~M
drug was assessed 3 minutes a~ter drug application.
Compounds o~ the invention gave percentage inhibition o~ plateau Ca2+ current in the range 30 to 100%.
W092/0~01 2 ~ ~ 3 ~ 9 0 PCT/GB91/01339 PHARMACEUTICAL FORMULATIONS
l. Formulation for intravenous infusion Compound of structure (I) O.l - 60 mg Sodium hydroxide/hydrochloric acid to pH ca 7 polyethylene glycol O - 30 ml propylene glycol O - 30 ml alcohol O - lO ml water to lOO ml 2. Formulation for bolus iniection Compound of structure ~I) O.l - 60 mg 15 sodium hydroxide or hydrochloric acid to pH ca 7 polyethylene glycol O - 2.5 ml alcohol O - 2.5 ml water to 5 ml A toxicity adjusting agent eg. sodium chloride, dextrose or mannitol may also be added.
3. Tablet for ora~ administration ma/tablet Compound of structure (I) 25 lactose lS3 starch 33 crospo~idone 12 microcrystalline cellulose 30 magnesium stearate 2 WO92/0~01 , PCT/GB9l/01339 2 ~
EXAMPLES
Intermediate PreParations (i) 3-(Hvdroxvmethvl)-l-PentvlPiPeridine A mixture of 3-~hydroxymethyl)piperidine (20g), 1-bromopentane (26.28g), potassium carbonate (24g) and ethanol ~400ml) was heated at reflux for 4 days. The solution was filtered, and the solvent removed under reduced prçssure. The residue was treated with acetone, filtered, the solvent removed and the resulting oil was distilled under reduced pre~sure to give the title compound as an o~ 24.63g, b.p. 103-104C @ 0.3mmHg.) (ii)3-(Hvdroxvmethvl)-l-ProPvlDiPeridine A mixture of 3-~hydroxymethyl)piperidine ~20g), 1-bromopropane (21.4g), potassium carbonate (24g) and ethanol (400ml) was heated at reflux for 1 days. The solution was filtered, and the solvent removed under reduced pressure. The residue was treated with acetone, filtered, the solvent removed and the resulting oil distilled under reduced pressure to give the title compound as an oil. (18.21 g, b.p. 101-103C Q 0.2mmHg.) (iii) l-Cinnamvl-3-(hvdroxYmethYl)~iPeridine A mixture of 3-(hydroxymethyl)piperidine (28g), cinnamyl bromide (47.91g), potassium carbonate (33.6g) and ethanol W092/02501 2 ~ PCT/GB9t/01339 ~300ml) was heated at reflux for 2 days. The solution was filtered, and the solvent removed under reduced pressure.
The residue was distilled under reduced pressure to give the title compound as an oil. (24.63g, b.p. 164-168 C @
0.3mmHg.) Found: C, 77.59; H, 9.18; N, 5.94%
(C15H21NO) requires: C, 77.88; H, 9.15; N, 6.05%
10 (iv) 3-Methanesul~honvloxvmethvl-l-PentvlPiPeridine hVdrochloride Methanesulphonyl chloride ~5.8ml) in dichloromethane ~20ml~ was added to a solution of 3-hydroxymethyl-1-pentylpiperidine (lOg) in dichloromethane (20ml). Themixture was stirred for 18 hours, treated with hydrogen chloride in ether and recrystallised from ethylacetate to give the title compound (13.2g) m.p. 99-101C
(v) 3-(3-HvdroxvProPvl)-l-PentvlPvridinium bromide A solution of 3-(3-hydroxypropyl)pyridine (20g), 1-bromopentane (22.05g) and acetone (250ml) was refluxed for 72 hours, cooled and poured into diethylether (200ml).
The oil which precipitated was collected by decantation then washed by decantation with diethyl ether (5 X lOOml) and dried at 50C (O.lmmHg) to give the title compound (42g)which was used without further purification.
(vi) 3-~3-HvdroxvProPvl)-l-pentvlpiPeridine W092/0250~j~t~ PCT/GB91/01339 A mixture of 3-(3-hydroxypropyl)-1-pentylpyridinium bromide ~42.g), platinum oxide (1.5g) and ethanol (350ml) was shaken under an atmosphere of hydrogen at 50 p.s.i.
for 1 hour. The mixture was filtered and the solvent S removed. The residue was dissolved in dilute sodium hydroxide (70ml) and extracted with dichloromethane (3 x 75ml). The organic extracts were combined, dried over magnesium sulphate and the solvent was removed to give the title compound as an oil (18.0g).
ExamPle 1 3-(4-FluoroPhenoxvmethYl)-l-PentvlPiperidine oxalate A solution of 3-(hydroxymethyl)-1-pentylpiperidine ~2.0g), 4-fluorophenol (1.21g) and triphenylphosphine (2.62g) in tetrahydrofuran (40ml) was treated with diethyl azodicarboxylate (1.74g) in tetrahydrofuran (lOml). The resulting solution was stirred at room temperature for 18 hours, the solvent was removed and the residue was chromatographed on silica gel eluted with methanol/dichloromethane. The resulting,,oil was dissolved in ethyl acetate (SOml) and treated with oxalic acid (0.62g). The precipitate was collected by filtration and recrystallised (methanol/ethyl acetate) to give the title compound (1.21g), m.p. 126 - 128C.
Found: C, 61.17; H, 7.79; N, 3.78; F 4.71%.
(C17H26FNO.C2H204.3H20) requires: C, 60.80; H, 7.60;
N, 3.70; F, 5.06%.
WO 92/02501 PCr/GB91/01339 xamPle 2 3- (3,4-MethYlenedioxYPhenoxvmethY~ -pentvlpiperidine hYdrochloride A solution of 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), sesamol (1.49g) and triphenylphosphine (2.62g) in tetrahydrofuran (50ml) was treated with diethyl azodicarboxylate (1.74g) in tetrahydrofuran (lOml~. The 10 resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with methanol/dichloromethane. The resulting oil was dissolved in ethyl acetate (50ml) and treated with ethereal hydrogen chloride. The precipitate 15 was collected by filtration and recrystallised (methanol/ethyl acetatel to give the title compound (l.Olg), m.p. 183 - 184C.
Found: C, 63.27; H, 8.22; N, 4.17; Cl, 10.37%.
(C18H27N03.HCl) requires: C, 63.25; H, 8.20; N, 4.10;
Cl, 10.40%.
ExamPle 3 25 3-(3-PhenYlPhenoxvmethvl)-l-PentYlpiperidine oxalate A solution of 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), 3-phenylphenol (1.70g) and triphenylphosphine (2.62g) in tetrahydrofuran (40ml) was treated with diethyl azodicarboxylate (1.66g) in tetrahydrofuran (50ml). The resulting solution was stirred at room temperature for 18 hours, the solvent was removed and the residue was W092/0~01 ~ PCT/&B91/01339 chromatographed on silica gel eluted with methanol/dichloromethane. The resulting oil (l.lg) was dissolved in ethyl acetate (SOml) and treated with oxalic acid (l.lequivalents). The precipitate was collected by filtration and recrystallised (methanol/ethyl acetate) to give the title compound ~0.8g), m.p. 148 - 14~C.
Found: C, 70.46; H, 7.80; N, 3.24%.
~C23H31NO.C2H204~ requires: C, 70.23; H, 7.78; N, 3.28%
Exam~le 4 3-(2-PhenYlphenox~methvl)-l-PentYlPiPeridine oxalate ~5 A 801ution of 3-~hydroxymethyl)-1-pentylpiperidine (2.0g), 2-phenylphenol ~1.70g) and triphenylphosphine ~2.62g) in tetrahydrofuran ~SOml) was treated with diethyl azodicarboxylate ~1.74g) in tetrahydrofuran (lOml). The resulting solution was stirred at room temperature for 18 hours, the solvent removed and the residue chromatographed on silica gel eluted with methanol/dichloromethane. The resulting oil was dissolved in ethyl acetate (50ml) and treated with oxalic acid (0.9g). The precipitate was collected by filtration and recrystallised (methanol/ethyl acetate) to give the title compound (l.lOg), m.p. 99 - 101C.
Found: C, 70.00; H, 7.97; N, 3.28%
(C23H31NO.C2H204) requires: C, 70.23; H, 7.78; N, 3.28%
W092/0~01 , PCT/GB91~01339 2 3 ~ a ExamPle 5 3-(4-BenzvloxvPhenoxvmethvl)-l-PentYlPiperidine hvdrochloride A solution of 3-(hydroxymethyl)-1-pentylpiperidine (2.0g), 4-benzyloxyphenol ~2.0g) and triphenylphosphine ~2.62g) in tetrahydrofuran ~50ml) was treated with diethyl azodicarboxylate ~1.74g) in tetrahydrofuran (lOml). The resulting solution was stirred at room temperature for 18 hours, the solvent remo~ed and the residue chromatographed on silica gel eluted with methanol/dichloromethane. The resultlng oil was dissol~ed ~n ethyl acetate and treated with hydrogen chloride in diethyl ether. The precipitate was collected by f~ltratlon and recrystallised ~methanol/ethyl acetate) to give the title compound (0.5g), m.p. 149 - 150C.
Found: C, 71.56; H, 8.71; N, 3.43; Cl, 8.57%
~C24H33N02.HCl) requires: C, 71.35; H, 8.48; N, 3.47;
Cl, 8.78%
ExamPle 6 3-(4-9enzvlPhenoxvmethYl)-l-PentvlPiperidine hvdrochloride The title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-pentylpiperidine ~2.0g), 4-hydroxydiphenylmethane (1.84g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride ga~e WO92/0~01 PCT~GB9t/01339 ~3~ 3 a white solid which was recrystallised from methanol/ethyl acetate (O.Slg), m.p. 169 - 171C.
Found: C, 74.38; H, 8.96; N, 3.68; Cl, 8.22%
~C24H33NO.HCl) requires: C, 74.30; H, 8.83; N, 3.61;
Cl, 9.16~
ExamPle 7 3-~3-TrifluoromethvlPhenoxvmethvl)-l-~entvlPiPeridine hvdrochloride The title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-pentylplperidine (1.85g), 3-trifluoromethylphenol (1.62g), triphenylphosphine ~2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate (0.41g), m.p. 165C.
Found: C, 59.04; H, 7.40; N, 3.91; Cl, 9.67%
(C18H26F3NO.HCl) requires: C, 59.0; H, 7.4; N, 3.8;
Cl, 9.7%
ExamPle 8 3-(4-Nitrophenoxvmethvl)-l-PentvlPiPeridine hvdrochloride The title compound was prepared in a similar manner to example 5 starting from 3-(hydroxymethyl)-1-pentylpiperidine (1.85g), 4-nitrophenol (1.39g), triphenylphosphine ~2.62g) and diethyl azodicarboxylate W092/0250l PCT/GB9l/01339 23(3~d9~
~1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate (0.13g), m.p. 220C.
S Found: C, 59.22; H, 7.96; N, 8.08; Cl, 10.31%
(C17H26N203.HCl) requires: C, 59.55; H, 7.94; N, 8.17;
Cl, 10.35%
ExamPle 9 3-~4-PhenYlPhenoxvmethvl)-l-PentvlPi~eridine oxalate The title compound was prepared in a similar manner to example 5 starting from 3-~hydroxymethyl)-1-pentyl-piperidine (2.0g), 4-phenylphenol ~1.70g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (0.60g), m.p. 173.5 - 174C.
Found: C, 70.17; H, 7.74; N, 3.50%
(C23H31NO.C2H204) requires: C, 70.23; H, 7.78; N, 3.28%
ExamPle 10 3-(2-BenzYlPhenoxvmethYl)-l-Pentylpiperidine oxalate The title compound was prepared in a similar manner to example 5 starting from 3-hydroxymethyl-1-pentylpiperidine (2.0g), 2-hydroxydiphenylmethane (1.84g), - triphenylphosphine ~2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a WO 92/02501 PCr/GB91/01339 2~ o white solid which was recrystallised from methanol/ethyl acetate ~0.260g), m.p. 120C.
Found: C, 70.21; H, 7.99; N, 3.20%
~C24H33NO.C2H204Ø25H20) requires: C, 69.94; H, 7.96;
N, 3.14%
ExamPle 1 1 10 3-(4-ChloroPhenoxvmethvl)-l-PentvlPiPeridine oxalate The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-penty}piperidine (2.0g), 4-chlorophenol (1.28g), triphenylphosphine ~2.62g) and 15 dlethyl azodlcarboxylate ~1.74g). Treating the product wlth oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate ~0.82g), m.p. 140C.
Found: C, 59.27; H, 7.26; N, 3.80; Cl, 8.93%
~C17H26ClNO.C2H204) requires: C, 59.14; H, 7.31; N, 3.63;
Cl, 9.1996 Examl~le 12 3-(4-Cvano~henoxvmethYl)-l-~entvlPi~eridine oxalate The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine ~2.0g), 4-cyanophenol ~1.19g), triphenylphosphine ~2.62g) and diethyl azodicarboxylate ~1.74gt. Treating the product with oxalic acid gave a white solid which was WO92/0~01 PCT/GB91/01339 9 ~
recrystallised from methanol/ethyl acetate (0.79g), m.p. 104C.
Found: C, 63.83; H, 7.59; N, 7.47%
(C18H26N2O~C2H2O4) requires: C, 63.81; H, 7.50; N, 7.44%
Exam~le 13 3-~henoxvmethvl-1-~entvlPi~eridine oxalate The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2 Og), phenol (0.94g), triphenylphosphine (2.62g) and diethyL
azodlcarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate (1.02g), m.p. 144.5C.
Found: C, 65.15; H, 8.43; N, 4.02%
~C17H27NO.C2H2O4) requires: C, 64.93; H, 8.32; N, 3.99%
ExamPle 14 3-(4-Fluorobenzvloxvmethvl)-1-PentvlPiPeridine oxalate A solution of 3-hydroxymethyl-1-pentylpiperidine (3.0g) in dimethylformamide (30 ml) was treated with sodium hydride (0.0162 mole) and then stirred for 0.5 hour when 4-fluorobenzyl chloride (2.35g) was added. The mixture was stirred for 2 days and the solvent removed. Water (100 ml) and dichloromethane (100 ml) were added and the organic layer was separated, washed with saturated sodium chloride (150 ml) and dried over magnesium sulphate. The W092/0~01 PCT/GB9l/01339 2~3~ 30 solvent was removed and the residue chromatographed on silica gel using methanol/d$chloromethane as eluent. The resulting oil was dissolved in ethyl acetate and treated with oxalic acid (1.1 mole equivalent). The precipitate was collected by filtration and recrystallised ~methanol/ethyl acetate) to give the title compound ~1.2g), m.p. 126 - 127C.
Found: C, 62.64; H, 7.97; N, 3.66%.
~C18H28FNO.C2H204) requires: C, 62.64; H, 7.89; N, 3.65%
ExamPle 15 3-~3,4-Meth~lenedioxvPhenoxYmethYl)-l-Propylpiperidine hYdrochlorlde The title compound was prepared in a similar manner to example 5 starting from 3-~hydroxymethyl)-1-propyl-piperidine ~1.57g), sesamol ~1.38g), triphenylphosphine ~2.62g~ and diethyl azodicarboxylate ~1.74g). Treating the product with hydrogen chloride gave a white solid which was recrystallised from methanol/ethyl acetate ~0.39g), m.p. 154C.
Found: C, 59.14; H, 7.63; N, 4.62; Cl, 10.77%
~C16H23N03.HCl.O.SH20) requires: C, 59.47; H, 7.74;
N, 4.34; Cl, 10.84%
WO92/02501 2 ~ ~ ~ d ~ V PCTJGB9l/01339 ~xamPle 16 l-Cinnamvl-3-(3,4-dichloroPhenoxvmethvl)PiPeridine oxalate The title compound was prepared in a similar manner to example 1 from 1-cinnamyl-3-hydroxymethylpiperidine ~2.00g), 3,4-dichlorophenol (1.41g), triphenylphosphine (2.27g) and diethyl azodicarboxylate (l.Slg). Treating the product with oxalic acid in ethyl acetate gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (1.27g), m.p.206C.
Found: C, 59.37; H, 5.46; N, 3.16; Cl, 15.16~
(C21H23C12NO~C2H2O4) requires C, 59.24; H, 5.40; N, 3.00;
Cl, 15.16%
ExamPle 17 l-Cinnamvl-3-~4-fluoroPhenoxvmethvlt~iPeridine oxalate The title compound was prepared in a similar manner to example 1 from 1-cinnamyl-3-hydroxymethylpiperidine (2.00g), 4-fluorophenol (0.971g), triphenylphosphine (2.27g) and diethyl azodicarboxylate (1.51g). Treating the product with oxalic acid in ethyl acetate gave a white solid which was recrystallised ~rom ethyl acetate/methanol to give the title compound as a white crystalline solid (0.7g), m.p.123C.
Found: C, 66.51; H, 6.31; N, 3.44%
(C2lH24FNo~c2H2o4) requires: C, 66.49; H, 6.31; N, 3.37 W092/0~01 PCT/GB91/01339 2 ~
ExamPle 18 3-(3,4-Dichloro~henoxYmethYl)-l-PentYlpi~eridine hvdrochlorlde The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.00g), 3,4-dichlorophenol (1.63g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (l.lOg), m.p.188-190C.
Found: C, 55.92; H, 7.18; N, 3.86; Cl , 9.64%
~C17H25C12NO~HCl) requlres: C, 55.67; H, 7.15; N, 3.82;
Cl-, 9.68%
ExamPle 1 9 3-(4-iso-ProPYlPhenoxvmethYl)-l-pentvlpiperidine hvdrochloride The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (2.00g), 4-iso-propylphenol (1.36g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to gi~e the title compound as a white crystalline solid (0.18g), m.p.172-174C.
Found: C, 70.41; H, 9.95; N, 4.34%
2 ~ 3 l~
(C20H33NO.HCl) requires: C, 70.66; H, 10.08; N, 4.12%
ExamPle 20 3-(3-iso-Pro~vlPhenoxvmethvl)-l-Pentvl~iPeridine hYdrochloride The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (1.5g), 3-iso-propylphenol (l.lg), triphenylphosphine (2.12g) and diethyl azodicarboxylate (1.41g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.8g), m.p.138-140C.
Found: C,-69.89; H, 9.91; N, 4.io; Cl , 10.33%
(C2oH33NO.HClØ25 H2O) requires: C, 69.74; H, 9.95; N, 4.07; Cl-, 10.29 ExamPle 21 3-(3-tert-ButvlPhenoxvmethvl)-l-PentvlPiPeridine hvdrochloride The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-penty}piperidine (1.50g), 3-tert-butylphenol (1.22g), triphenylphosphine (2.12g) and diethyl azodicarboxylate (1.41g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the - 30 title compound as a white crystalline solid (1.035g), m.p.185-187C.
Found: C, 71.39; H, 10.33; N, 4.09; Cl, 9.92%
~C21H35NO.HCl) requires: C, 71.26; H, 10.25; N, 3.96;
Cl,10.02%
ExamPle 22 3-(4-Fluorobenzvlaminomethvl)-PentvlPiPeridine dihvdrochloride A mixture of 4-fluorobenzylamine ~2.49g) and 3-methanesulphonyloxymethyl-l-pentylpiperidine hydrochloride (2g) was heated at 150C for 2.5 hours. The mixture was dissolved in dichloromethane and the dichloromethane solution washed with dilute sodium hydroxide solution, drled over sodium sulphate and the solvent removed. The residue was chromatographed on silica gel with d~chloromethane - methanol as eluent and treated with hydrogen chloride in ether to give a solid.
Recrystallisation from ethyl acetate gave the title compound (0.92g), m.p. 207-209C.
Found: C, 58.12; H, 8.55; N, 7.67; Cl, 19.41%
(C18H29FN2.2HClØ3H20) requires: C, 58.26; H, 8.57; N, 7.54; Cl, 19.09%
ExamPle 23 3-(4-FluoroPhenvlaminomethvl~-PentvlPiPeridine dihvdrochloride Substituting 4-fluoroaniline for 4-fluorobenzylamine (9.12g) in example 22 gave the title compound (0.593g) as a white microcrystaline solid. m.p. 196-198C
WO g2/02501 2 ~ 3 ~ PCr/GBgl/0133g Found: C, 56.77; H, 8.12; N, 7.83; Cl, 19.63%
(C17H27FN2.2HC1Ø5H20) requires: C, 56.66; H, 8.39; N, 7.77; Cl, 19.68%
Exam~le 24 3-(3,4-DichloroPhenYlaminomethvl)-PentvlPiPeridine dihvdrochloride Substituting 3,4-dichloroaniline for 4-fluorobenzylamine (4.04g) in example 22 gave the title compound (0.38g) as a white microcrystaline solid. m.p. 185-187C
Found: C, 50.99; H, 7.02; N, 6.99%
~C17H26C12N2.2HCl) requires: C, 50.76; H, 7.027 N, 6.96 ExamPle 25 3-(4-tert-ButvlPhenoxYmethvl)-1-PentvlPiPeridine hvdrochloride The title compound was prepared in a similar manner to example 1 from 3-hydroxymethyl-1-pentylpiperidine (l.SOg), 4-tert-butylphenol (1.22g), triphenylphosphine (2.12g) and diethyl azodicarboxylate (1.41g). Treating the product with hydrogen chloride in ether gave a white solid which was recrystallised from ethyl acetate/methanol to give the title compound as a white crystalline solid (0.205g), m.p.197-199C.
Found: C, 70.98; H, 10.21; N, 4.00; Cl, 9.82%
23~9~
tC21H35NO.HCl) requires: C, 71.26; H, 10.25; N, 3.96;
Cl,10.02%
~xamPle 26 3- r 3-(4-Fluoro~henoxv)ProPvll-l-PentvlPiperidine oxalate The title compound was prepared in a similar manner to example 1 from 1-pentyl-3-(3-hydroxypropyl)piperidine (2.13g), 4-fluorophenol tl.l2g), triphenylphosphine (2.62g) and diethyl azodicarboxylate (1.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate tl.lOg), m.p.
115 - 118C.
1~ Found: C, 63.53; H, 8.11; N, 3.80~
tClgH30FNO.C2H204) requires: C, 63.4B; H, 8.06; N, 3.53%
ExamPle 27 3-r3-(3,4-DichloroPhenoxv)~roPvll-l-pentylpiperidine oxalate The title compound was prepared in a similar manner to example 1 from 1-pentyl-3-t3-hydroxypropyl)piperidine t2.13g), 3,4-dichlorophenol tl.63g), triphenylphosphine ~2.62g) and diethyl azodicarboxylate tl.74g). Treating the product with oxalic acid gave a white solid which was recrystallised from methanol/ethyl acetate tO.Sg), m.p.
127-130C.
Found: C, 56.35; H, 6.90; N, 3.25%
tClgH2gC12NO.C2H204) requires: C, 56.25; H, 6.97; N, 3.12%
WO92/02501 2 ~ 8 3 ~ Pcr/GBgliol339 ExamPle 28 a) ~-)-3-(4-BenzYloxvPhenoxvmethYl)-l-pentvlPiPeridine b) ~ 3-~4-BenzvloxYPhenoxYmethYl)-l-~entvlplperidine The product from example 5 (55mg) was partitioned between diethyl ether and dilute sodium bicarbonate solution. The ether phase was separated, dried and the solvent removed.
The residue was chromatographed on a Chiralcel OJ h.p.l.c.
chromatography column using ethanol/hexane as eluent. The two enant, ~ers were collected. The (-) enantiomer being eluted first. Yield (8.0mg) rotation (-1.38 @ 22C in methanol). The second peak gave the (+) enantiomer, yield ~7.2mg) rotation ~1.24 @ 22C in methanol).
ExamPle 29 3-(3,4-DichlorobenzvlaminomethYl)-l-PentvlPiPeridine dihvdrochloride Substituting 3,4-dichlorobenzylamine for 4-fluorobenzylamine (0.587g) in example 22 gave the title compound (0.46g) as a white microcrystaline solid. m.p.
Found: C, 51.55; H, 7.09; N, 6.73; Cl, 16.85%
(C18H28C12N2.2HCl) requires: C, 51.94; H, 7.26; N, 6.73;
Cl, 17.04%
Claims (14)
1. A compound of structure (I):
(I) in which R is C1-8alkyl(phenyl)p, C2-8alkenyl(phenyl)p, C2-8alkynyl(phenyl)p, C3-8cycloalkyl or C1-8alkylC3-8cycloalkyl;
p is 0 to 2;
n is 0 to 6;
A is a bond, oxygen, sulphur or NR1;
R1 is hydrogen, C1-8alkyl or phenylC1-4alkyl;
m is 0 to 3; and Ar is aryl or heteroaryl, each of which may be optionally substituted, or a salt thereof.
(I) in which R is C1-8alkyl(phenyl)p, C2-8alkenyl(phenyl)p, C2-8alkynyl(phenyl)p, C3-8cycloalkyl or C1-8alkylC3-8cycloalkyl;
p is 0 to 2;
n is 0 to 6;
A is a bond, oxygen, sulphur or NR1;
R1 is hydrogen, C1-8alkyl or phenylC1-4alkyl;
m is 0 to 3; and Ar is aryl or heteroaryl, each of which may be optionally substituted, or a salt thereof.
2. A compound according to claim 1 wherein R is C1-8alkyl, phenyl(C1-8)alkyl or phenyl(C2-8)alkenyl.
3. A compound according to claim 1 or claim 2 in which A is oxygen.
4. A compound according to any of claims 1 to 3 wherein n is 0 to 3.
5. A compound according to any of claims 1 to 4 wherein m is 0 to 3.
6. A compound according to any of claims 1 to 5 in which Ar is optionally substituted phenyl.
7. A compound according to claim 1 which is:
3-(4-fluorophenoxymethyl)-1-pentylpiperidine, 3-(3,4-methylenedioxyphenoxymethyl)-1-pentylpiperidine, 3-(3-trifluoromethylphenoxymethyl)-1-pentylpiperidine, 3-(3-phenylphenoxymethyl)-1-pentylpiperidine, 3-(2-phenylphenoxymethyl)-1-pentylpiperidine, 3-(4-phenylphenoxymethyl)-1-pentylpiperidine, 3-(2-benzylphenoxymethyl)-1-pentylpiperidine, 3-(4-benzylphenoxymethyl)-1-pentylpiperidine, 3-(4-benzyloxyphenoxymethyl)-1-pentylpiperidine, 1-cinnamyl-3-(3,4-dichlorophenoxymethyl)piperidine, 3-(4-iso-propylphenoxymethyl)-1-pentylpiperidine; or 3-(3,4-dichlorophenylaminomethyl)-1-pentylpiperidine; or a pharmaceutically acceptable salt thereof.
3-(4-fluorophenoxymethyl)-1-pentylpiperidine, 3-(3,4-methylenedioxyphenoxymethyl)-1-pentylpiperidine, 3-(3-trifluoromethylphenoxymethyl)-1-pentylpiperidine, 3-(3-phenylphenoxymethyl)-1-pentylpiperidine, 3-(2-phenylphenoxymethyl)-1-pentylpiperidine, 3-(4-phenylphenoxymethyl)-1-pentylpiperidine, 3-(2-benzylphenoxymethyl)-1-pentylpiperidine, 3-(4-benzylphenoxymethyl)-1-pentylpiperidine, 3-(4-benzyloxyphenoxymethyl)-1-pentylpiperidine, 1-cinnamyl-3-(3,4-dichlorophenoxymethyl)piperidine, 3-(4-iso-propylphenoxymethyl)-1-pentylpiperidine; or 3-(3,4-dichlorophenylaminomethyl)-1-pentylpiperidine; or a pharmaceutically acceptable salt thereof.
8. A process for preparing a compound of structure (I) which comprises:
(a) for compounds of structure (I) in which A is O, S or NR1, reaction of a compound of structure (II):
(II) in which R and n are as described for structure (I) and A1 is o, S or NR1, with a compound of structure L(CH2)mAr in which m and Ar are as described for structure (I), and L is a leaving group;
(b) for compounds of structure (I) in which A is O, S or NR1, reaction of a compound of structure (III):
(III) in which n and R are as described for structure (I) and L1 is a group displaceable by a nucleophile, with a compound of structure HA1(CH2)mAr where m and Ar are as described for structure (I) and A1 is as described for structure (II); or (c) for compounds of structure (I) in which A is NR1, reduction of a compound of structure (IV) :
(IV) in which R4 represents the group or , and n, m, R and Ar are as described for structure (I);
(d) for compounds of structure (I) in which A is a bond, reaction of a compound of structure (V) :
(V) (wherein R, L1, m and n are as hereinbefore defined).
with a compound of structure X1Ar in which Ar is as described for structure (I), and X1 is an alkali metal;
(e) introduction of the group R into a compound of formula (VI) :
(VI) by reaction with a compound RL2, wherein L2 is a leaving group;
(f) Reduction of a compound of formula (VII) :
(VII) wherein R5 is C1-7alkyl(phenyl)p, C2-7alkenyl(phenyl)p, C2-7alkynyl(phenyl)p or C1-7aIkylC3-8cycloalkyl;
(g) Reduction of a compound of structure (VIII):
(VIII) wherein R, A, Ar m and n are as hereinbefore defined and ? is a counter ion;
and optionally thereafter forming a salt.
(a) for compounds of structure (I) in which A is O, S or NR1, reaction of a compound of structure (II):
(II) in which R and n are as described for structure (I) and A1 is o, S or NR1, with a compound of structure L(CH2)mAr in which m and Ar are as described for structure (I), and L is a leaving group;
(b) for compounds of structure (I) in which A is O, S or NR1, reaction of a compound of structure (III):
(III) in which n and R are as described for structure (I) and L1 is a group displaceable by a nucleophile, with a compound of structure HA1(CH2)mAr where m and Ar are as described for structure (I) and A1 is as described for structure (II); or (c) for compounds of structure (I) in which A is NR1, reduction of a compound of structure (IV) :
(IV) in which R4 represents the group or , and n, m, R and Ar are as described for structure (I);
(d) for compounds of structure (I) in which A is a bond, reaction of a compound of structure (V) :
(V) (wherein R, L1, m and n are as hereinbefore defined).
with a compound of structure X1Ar in which Ar is as described for structure (I), and X1 is an alkali metal;
(e) introduction of the group R into a compound of formula (VI) :
(VI) by reaction with a compound RL2, wherein L2 is a leaving group;
(f) Reduction of a compound of formula (VII) :
(VII) wherein R5 is C1-7alkyl(phenyl)p, C2-7alkenyl(phenyl)p, C2-7alkynyl(phenyl)p or C1-7aIkylC3-8cycloalkyl;
(g) Reduction of a compound of structure (VIII):
(VIII) wherein R, A, Ar m and n are as hereinbefore defined and ? is a counter ion;
and optionally thereafter forming a salt.
9. A pharmaceutical composition comprising a compound of structure (I) as claimed in any of claims 1 to 7 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.
10. A compound of structure (I) according to any of claims 1 to 7 or a pharmaceutically acceptable salt thereof for use in therapy.
11. Use of a compound of structure (I) according to any of claims 1 to 7 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of conditions caused or exacerbated by the accumulation of calcium in the brain cells of mammals.
12. A method of treatment of a condition caused or exacerbated by the accumulation of calcium in the brain cells of mammals which comprises administering to a subject in need thereof an effective amount of a compound of structure (I) according to any of claims 1 to 7 or a pharmaceutically acceptable salt thereof.
13. A method according to claim 12 wherein the condition is stroke.
14. A method according to claim 12 or claim 13 wherein the mammal is a human.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9017225.5 | 1990-08-06 | ||
GB909017225A GB9017225D0 (en) | 1990-08-06 | 1990-08-06 | Compounds |
GB909021852A GB9021852D0 (en) | 1990-10-08 | 1990-10-08 | Compounds |
GB9021852.0 | 1990-10-08 | ||
GB9107780.0 | 1991-04-12 | ||
GB919107780A GB9107780D0 (en) | 1991-04-12 | 1991-04-12 | Compounds |
PCT/GB1991/001339 WO1992002501A1 (en) | 1990-08-06 | 1991-08-05 | 3-substituted piperidine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2088490A1 true CA2088490A1 (en) | 1992-02-07 |
Family
ID=27265217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002088490A Abandoned CA2088490A1 (en) | 1990-08-06 | 1991-08-05 | 3-substituted piperidine derivatives |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0542844A1 (en) |
JP (1) | JPH06500092A (en) |
CN (1) | CN1062349A (en) |
AP (1) | AP236A (en) |
AU (1) | AU649468B2 (en) |
CA (1) | CA2088490A1 (en) |
IE (1) | IE912760A1 (en) |
IL (1) | IL99074A0 (en) |
MA (1) | MA22251A1 (en) |
MX (1) | MX9100517A (en) |
NZ (1) | NZ239267A (en) |
PT (1) | PT98575A (en) |
TW (1) | TW239860B (en) |
WO (1) | WO1992002501A1 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5290789A (en) * | 1992-11-20 | 1994-03-01 | Sterling Wintrop Inc. | Penta and tetrasubstituted piperidines and compositions and method of treating psychosis |
GB9226111D0 (en) * | 1992-12-15 | 1993-02-10 | Smithkline Beecham Plc | Madicaments |
GB9314973D0 (en) * | 1993-07-20 | 1993-09-01 | Smithkline Beecham Plc | Medicaments |
GB9319534D0 (en) * | 1993-09-22 | 1993-11-10 | Boots Co Plc | Therapeutic agents |
WO1995024390A1 (en) * | 1994-03-11 | 1995-09-14 | Smithkline Beecham Plc | Novel phenyl(-alkyl/alkoxy)-1-aminoalkyl-substituted piperidines and pyrrolidines as calcium channel antagonists |
US5770575A (en) * | 1994-03-16 | 1998-06-23 | Ortho Pharmaceutical Corporation | Nipecotic acid derivatives as antithrombotic compounds |
GB9411052D0 (en) * | 1994-06-02 | 1994-07-20 | Smithkline Beecham Plc | Medicaments |
GB9411045D0 (en) * | 1994-06-02 | 1994-07-20 | Smithkline Beecham Plc | Compounds and use |
US5843983A (en) * | 1996-02-15 | 1998-12-01 | Sankyo Company, Limited | Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use |
CA2232147A1 (en) * | 1997-04-03 | 1998-10-03 | F. Hoffmann-La Roche Ag | Phenoxymethyl piperidine derivatives |
US6110937A (en) | 1997-04-03 | 2000-08-29 | Syntex Usa, Inc. | Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain |
US6251919B1 (en) | 1998-02-27 | 2001-06-26 | Warner-Lambert | Heterocyclic substituted aniline calcium channel blockers |
US6166052A (en) | 1998-03-11 | 2000-12-26 | Warner-Lambert Company | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers |
CA2340341A1 (en) * | 1998-08-12 | 2000-02-24 | Smithkline Beecham Corporation | Calcilytic compounds |
AU2003238046A1 (en) * | 2002-06-27 | 2004-01-19 | Actelion Pharmaceuticals Ltd | Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease |
WO2017034994A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity |
HK1260897A1 (en) | 2015-08-21 | 2019-12-27 | Portola Pharmaceuticals, Inc. | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity |
WO2017034997A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use |
WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2310762A1 (en) * | 1975-05-16 | 1976-12-10 | Roussel Uclaf | NEW DERIVATIVES N-SUBSTITUTES OF PHENYL PIPERIDINE AND THEIR SALTS, METHOD OF PREPARATION AND APPLICATION AS MEDICINAL PRODUCTS |
DE2950135A1 (en) * | 1979-12-13 | 1981-06-19 | Merck Patent Gmbh, 6100 Darmstadt | BASIC AETHER, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND METHOD FOR THE PRODUCTION THEREOF |
FR2510112A1 (en) * | 1981-07-24 | 1983-01-28 | Roussel Uclaf | NOVEL DERIVATIVES OF 2-OXO-PYRID-3-YL OR PIPERIDIN-3-YL INDOLE, THEIR SALTS, PREPARATION METHOD, MEDICAMENT APPLICATION AND COMPOSITIONS COMPRISING THE SAME |
ZA848275B (en) * | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
CA1260474A (en) * | 1984-12-03 | 1989-09-26 | Raymond A. Stokbroekx | Benzoxazol- and benzothiazolamine derivatives |
NZ219646A (en) * | 1986-03-27 | 1990-10-26 | Merck Sharp & Dohme | Oxadiazole derivatives of azacyclics for treating cns disorders |
IL83275A (en) * | 1986-09-08 | 1994-02-27 | Novo Nordisk As | Substituted 1, 2, 4- oxadiazolyl piperidine compounds, their preparation and pharmaceutical compositions containing them |
EP0307141B1 (en) * | 1987-09-10 | 1993-01-13 | MERCK SHARP & DOHME LTD. | Oxazoles and thiazoles for the treatment of senile dementia |
FR2636946B1 (en) * | 1988-09-23 | 1990-11-02 | Lipha | ((DIARYLMETHOXY) ALCOYL) -1 PYRROLIDINES AND PIPERIDINES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM |
DE3834860A1 (en) * | 1988-10-13 | 1990-04-19 | Basf Ag | HETEROCYCLICALLY SUBSTITUTED ALKOXYCUMARINES, METHOD FOR THE PRODUCTION THEREOF AND THERAPEUTIC AGENTS CONTAINING THEM |
-
1991
- 1991-08-02 MX MX9100517A patent/MX9100517A/en unknown
- 1991-08-02 IE IE276091A patent/IE912760A1/en unknown
- 1991-08-04 IL IL99074A patent/IL99074A0/en unknown
- 1991-08-05 AU AU83243/91A patent/AU649468B2/en not_active Ceased
- 1991-08-05 JP JP3513951A patent/JPH06500092A/en active Pending
- 1991-08-05 CN CN91105944A patent/CN1062349A/en active Pending
- 1991-08-05 TW TW080106122A patent/TW239860B/zh active
- 1991-08-05 NZ NZ239267A patent/NZ239267A/en unknown
- 1991-08-05 CA CA002088490A patent/CA2088490A1/en not_active Abandoned
- 1991-08-05 PT PT98575A patent/PT98575A/en not_active Application Discontinuation
- 1991-08-05 WO PCT/GB1991/001339 patent/WO1992002501A1/en not_active Application Discontinuation
- 1991-08-05 MA MA22530A patent/MA22251A1/en unknown
- 1991-08-05 EP EP91914530A patent/EP0542844A1/en not_active Withdrawn
- 1991-08-06 AP APAP/P/1991/000314A patent/AP236A/en active
Also Published As
Publication number | Publication date |
---|---|
AP9100314A0 (en) | 1991-10-31 |
PT98575A (en) | 1992-06-30 |
CN1062349A (en) | 1992-07-01 |
MX9100517A (en) | 1992-04-01 |
EP0542844A1 (en) | 1993-05-26 |
AP236A (en) | 1993-02-24 |
TW239860B (en) | 1995-02-01 |
MA22251A1 (en) | 1992-04-01 |
WO1992002501A1 (en) | 1992-02-20 |
AU8324391A (en) | 1992-03-02 |
NZ239267A (en) | 1994-05-26 |
AU649468B2 (en) | 1994-05-26 |
JPH06500092A (en) | 1994-01-06 |
IL99074A0 (en) | 1992-07-15 |
IE912760A1 (en) | 1992-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP279A (en) | 4 substituted piperidine derivatives, processes for their preparation pharmaceutical compositions containing them and their use in therapy. | |
CA2088490A1 (en) | 3-substituted piperidine derivatives | |
EP0160422A1 (en) | N-Aryl-N-(4-Piperidinyl)amides and pharmaceutical compositions and methods employing such compounds | |
WO1993015052A1 (en) | Compounds as calcium channel antagonists | |
CA2112397A1 (en) | Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them | |
EP0374801A2 (en) | Novel N-sustituted azaheterocyclic carboxylic acids | |
US4879300A (en) | Novel piperidine derivatives | |
WO1994013291A1 (en) | Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives | |
US5332817A (en) | 3-aminopiperidine derivatives and related nitrogen containing heterocycles | |
AU5833494A (en) | Piperidine derivatives as calcium channel antagonists | |
US4166120A (en) | Analgesic and tranquilizing benzoylpropyl-spiro[dihydrobenzofuran]piperidines and pyrrolidines | |
EP0399414B1 (en) | Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same | |
WO1992022527A2 (en) | 3-substituted pyrrolidine derivatives as calcium channel antagonists | |
JPH06500076A (en) | Piperidine compounds, their synthesis and methods of use | |
RU2418794C2 (en) | Isoquinoline and benzo[h]isoquinoline derivatives, their obtaining and their application in therapy as antagonists of histamine h3 receptor | |
JPH04226959A (en) | N-substituted trifluoromethylphenyltetrahydropyridine and pharmaceutical compositions containing the same | |
WO1995003302A1 (en) | Quinolizidines with calcium channel antagonistic activity | |
JPS6337111B2 (en) | ||
WO1995024390A1 (en) | Novel phenyl(-alkyl/alkoxy)-1-aminoalkyl-substituted piperidines and pyrrolidines as calcium channel antagonists | |
EP0125315A1 (en) | Phenoxyaminopropanol derivatives | |
US5198451A (en) | Heterocyclic carboxylic acids | |
AU703776B2 (en) | Derivatives of 4-(cycloalkyl)piperidines and of 4-(cycloalkylalkyl)piperidines, their preparation and their therapeutic application | |
US4452809A (en) | Trans-4-(2-chlorophenoxy)-1-ethyl-3-pyrrolidinol and anti-depressant use thereof | |
US5608069A (en) | 1-substituted, 3-carboxylic acid piperidine derivatives | |
CA1132989A (en) | N-[3-(4-fluorobenzoyl) propyl]spiro[dihydrobenzofuranpiperidine and - pyrrolidine]s, derivatives thereof, process for their manufacture and their use as medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |